{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":247,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":247,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"4aa5585a87ca","filters":{"venue":"SKIN The Journal of Cutaneous Medicine"}},"results":[{"id":"W3103502969","doi":"10.25251/skin.4.supp.95","title":"Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"Incyte","keywords":"Ruxolitinib; Atopic dermatitis; Double blind; Medicine; Dermatology; Randomized controlled trial; Internal medicine; Alternative medicine; Myelofibrosis; Pathology; Placebo","authors":[{"name":"Kim Papp","is_ca":true},{"name":"Jacek C. Szepietowski","is_ca":false},{"name":"Leon Kircik","is_ca":false},{"name":"Darryl Toth","is_ca":true},{"name":"Michael E. Kuligowski","is_ca":false},{"name":"May E. Venturanza","is_ca":false},{"name":"Kang Sun","is_ca":false},{"name":"Eric L. Simpson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05448425355856354,"gpt":0.3643731436587562,"spread":0.3098888901001927,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00468403,0.001514936,0.004080602,0.0004913695,0.0006489368,0.001262189,0.001155032,0.002441012,0.004187948],"category_scores_gemma":[0.003505778,0.0007589004,0.002716588,0.0005110345,0.001486884,0.001569671,0.0003169203,0.002794919,0.000820911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006696373,"about_ca_system_score_gemma":0.000984716,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000555223,"about_ca_topic_score_gemma":0.001122478,"domain_scores_codex":[0.9983445,0.0008810816,0.0001893452,0.0002388813,0.0001830521,0.0001631009],"domain_scores_gemma":[0.9973204,0.001214997,0.0006465215,0.0002627794,0.000195097,0.0003602802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9469391,0.008914887,0.0005682901,0.001673765,0.002025017,0.00004539854,0.00008361425,0.0002831046,0.009311096,0.00007229271,0.0005241466,0.02955936],"study_design_scores_gemma":[0.920344,0.07305656,0.003027098,0.00006738975,0.001265725,0.00006103963,0.00002060651,0.0002833164,0.001260465,0.00009264182,0.0004955731,0.0000254545],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9703293,0.01948449,0.001678561,0.0005181795,0.0004397856,0.004413408,0.001250826,0.0001646622,0.001720704],"genre_scores_gemma":[0.9846094,0.006973553,0.002153604,0.0008277103,0.0005077363,0.00281683,0.001040171,0.00004013077,0.001030897],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00468403,"threshold_uncertainty_score":0.02477181,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3102502247","doi":"10.25251/skin.4.supp.75","title":"Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Innovaderm (Canada); Probity Medical Research; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Psoriasis; Medicine; Dermatology; Phase (matter); Clinical trial; Internal medicine; Physics","authors":[{"name":"Mark Lebwohl","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"Bruce Strober","is_ca":false},{"name":"April W. Armstrong","is_ca":false},{"name":"Hwanhee Hong","is_ca":true},{"name":"Leon Kircik","is_ca":false},{"name":"Jennifer Soung","is_ca":false},{"name":"Jeff Fromowitz","is_ca":false},{"name":"Scott Guenthner","is_ca":false},{"name":"Stephen C. Piscitelli","is_ca":false},{"name":"David S. Rubenstein","is_ca":false},{"name":"Philip Brown","is_ca":false},{"name":"Anna M. Tallman","is_ca":false},{"name":"Robert Bissonnette","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06043474788367265,"gpt":0.3426864154785979,"spread":0.2822516675949253,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001956882,0.001442965,0.002008034,0.0003759977,0.0003737327,0.001240442,0.0007004694,0.001819896,0.006825051],"category_scores_gemma":[0.001309038,0.0005507972,0.001925687,0.0004374024,0.0007424321,0.0009586447,0.000227281,0.003031943,0.001242758],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000619286,"about_ca_system_score_gemma":0.0009851204,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008698977,"about_ca_topic_score_gemma":0.002732509,"domain_scores_codex":[0.9996444,0.0001510465,0.000020264,0.00005419082,0.00005216269,0.00007793877],"domain_scores_gemma":[0.9992167,0.0002665368,0.0001505292,0.00006247501,0.00007826561,0.0002254891],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7194198,0.02538437,0.00158893,0.005406003,0.003373686,0.0003729928,0.0003765282,0.00161932,0.03808392,0.0006722995,0.0100817,0.1936204],"study_design_scores_gemma":[0.8045804,0.1771709,0.006384299,0.0003869932,0.00122227,0.0003794257,0.00008535675,0.0008642235,0.002033417,0.0005226521,0.006315379,0.00005467131],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9166073,0.05497437,0.002603449,0.003239368,0.0009896685,0.007466379,0.003866946,0.000421879,0.009830725],"genre_scores_gemma":[0.9529811,0.03017393,0.002935666,0.002687459,0.000507233,0.003233714,0.002485376,0.00007213152,0.004923393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006825051,"threshold_uncertainty_score":0.0228321,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4229015785","doi":"10.25251/skin.6.supp.s29","title":"Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"LEO Pharma","keywords":"Atopic dermatitis; Medicine; Dermatology; Phase (matter); Pediatrics; Physics","authors":[{"name":"Amy S. Paller","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Weily Soong","is_ca":false},{"name":"Shinichi Imafuku","is_ca":false},{"name":"Chih-ho Hong","is_ca":true},{"name":"Marie L. A. Schuttelaar","is_ca":false},{"name":"Petra Amoudruz","is_ca":false},{"name":"Azra Kurbasic","is_ca":false},{"name":"Lise Soldbro","is_ca":false},{"name":"Katja Wendicke Lophaven","is_ca":false},{"name":"Michael J. Cork","is_ca":false},{"name":"Anthony Bewley","is_ca":false},{"name":"Eric L. Simpson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01069320491428947,"gpt":0.2697512616344214,"spread":0.2590580567201319,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001258468,0.0004850707,0.001115459,0.0001261418,0.0002614507,0.0007108322,0.0003680065,0.0007153453,0.001915647],"category_scores_gemma":[0.001017986,0.000213489,0.001939066,0.0001342776,0.0003838487,0.0004679648,0.0001463228,0.002377053,0.0003161167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005391313,"about_ca_system_score_gemma":0.0006188918,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006330069,"about_ca_topic_score_gemma":0.002179835,"domain_scores_codex":[0.9995999,0.0001895554,0.0000267602,0.0000632387,0.00005643932,0.00006400373],"domain_scores_gemma":[0.9993382,0.0002084083,0.0001872494,0.00003993711,0.00004531851,0.0001808553],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8115718,0.009623481,0.02278983,0.002347542,0.005634915,0.0003568457,0.0002518683,0.001440897,0.01679977,0.0003411083,0.005168128,0.1236738],"study_design_scores_gemma":[0.6745984,0.1953765,0.1106624,0.0004767216,0.005631234,0.001081792,0.0002152455,0.001571777,0.003704354,0.0004474061,0.006173536,0.00006062465],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894373,0.007960714,0.0001415226,0.0003920477,0.0001173886,0.0002087483,0.0005163726,0.00002670435,0.001199157],"genre_scores_gemma":[0.9949033,0.00267735,0.0002826185,0.0005451414,0.00009977088,0.0001963284,0.0005132933,0.000009412598,0.000772792],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001915647,"threshold_uncertainty_score":0.006655455,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3135451264","doi":"10.25251/skin.5.supp.32","title":"Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Mental Health and Psychiatry","field":"Arts and Humanities","cited_by":9,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University","funders":"","keywords":"Disease; Perception; Medicine; Psoriasis; Dermatology; Psychology; Pathology; Neuroscience","authors":[{"name":"Mark Lebwohl","is_ca":false},{"name":"Richard G. Langley","is_ca":true},{"name":"C. Paul","is_ca":false},{"name":"L. Puig","is_ca":false},{"name":"Kristian Reich","is_ca":false},{"name":"Peter van der Kerkhof","is_ca":false},{"name":"Sven Richter","is_ca":false},{"name":"Benolt Guerette","is_ca":false},{"name":"Paolo Gisondi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05909140626378356,"gpt":0.2805296217580594,"spread":0.2214382154942758,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00347674,0.0001128646,0.0003222736,0.0006046696,0.0007684309,0.001072417,0.0002667656,0.0006251822,0.001915379],"category_scores_gemma":[0.01093815,0.0001583951,0.0006335667,0.0006269756,0.0005641271,0.0009271781,0.001460269,0.001321324,0.0002638678],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008705826,"about_ca_system_score_gemma":0.0009482956,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00736096,"about_ca_topic_score_gemma":0.008061706,"domain_scores_codex":[0.9979188,0.0009497252,0.0002330653,0.0001487548,0.0004540347,0.0002956013],"domain_scores_gemma":[0.9924167,0.002059325,0.003035335,0.0003272803,0.0009422316,0.001219102],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000209208,0.0002786049,0.982389,0.00004005169,0.00008099072,0.00006153967,0.005568516,0.00007268939,0.0001990031,0.00006953522,0.0007923848,0.01023858],"study_design_scores_gemma":[0.00001304678,0.0002772807,0.9905201,0.00001912436,0.00002317696,0.00008984363,0.008000047,0.0001624219,0.00006686705,0.00004959574,0.0007657959,0.00001263278],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984347,0.00005675096,0.00004196234,0.0003153999,0.000005228814,0.0000227739,0.0002029429,0.000002428991,0.0009177389],"genre_scores_gemma":[0.9993123,0.0000604617,0.0001116768,0.0001460443,0.000005813333,0.0000202163,0.0001622197,0.000001866881,0.0001793852],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00736096,"threshold_uncertainty_score":0.01838696,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388626033","doi":"10.25251/skin.7.supp.286","title":"Spesolimab for Hidradenitis Suppurativa: A Proof-of-Concept Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SKiN Health","funders":"","keywords":"Hidradenitis suppurativa; Medicine; Placebo; Internal medicine; Dosing; Intertriginous; Adverse effect; Gastroenterology; Adalimumab; Surgery; Pathology; Tumor necrosis factor alpha","authors":[{"name":"Afsáneh Alavi","is_ca":false},{"name":"Errol P. Prens","is_ca":false},{"name":"Alexa B. Kimball","is_ca":true},{"name":"James G. Krueger","is_ca":false},{"name":"Sutirtha Mukhopadhyay","is_ca":false},{"name":"Hui Wang","is_ca":false},{"name":"Nathalie Ivanhoff","is_ca":false},{"name":"A.C. Hernández","is_ca":false},{"name":"Christos C. Zouboulis","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03057522950790823,"gpt":0.3238723228457288,"spread":0.2932970933378206,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004226682,0.001548741,0.001362264,0.0003904138,0.0002515218,0.001221551,0.000874746,0.001469483,0.005812435],"category_scores_gemma":[0.001253538,0.0003641909,0.00193763,0.0002835655,0.0005831784,0.0007455194,0.0004010413,0.002438138,0.001314753],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005180499,"about_ca_system_score_gemma":0.001645954,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001568641,"about_ca_topic_score_gemma":0.0004252089,"domain_scores_codex":[0.9992254,0.0003717762,0.00004774132,0.00008726525,0.0001511381,0.0001165938],"domain_scores_gemma":[0.9990496,0.0002372985,0.0002333272,0.00006712976,0.0001356448,0.0002770444],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1868001,0.07053368,0.003094547,0.0229741,0.004346145,0.001909856,0.0005940634,0.003450399,0.3326042,0.001962432,0.02565305,0.3460774],"study_design_scores_gemma":[0.3017367,0.5812956,0.007961035,0.001149905,0.00246888,0.003017812,0.0001432364,0.001749334,0.03670371,0.0007418978,0.06295233,0.00007946201],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.852337,0.09258215,0.01451114,0.004718138,0.001930424,0.01686107,0.006091322,0.0005402801,0.01042844],"genre_scores_gemma":[0.9240038,0.03779347,0.01315338,0.004375774,0.001124184,0.008413979,0.004852719,0.00005695776,0.006225727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005812435,"threshold_uncertainty_score":0.02235311,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3120199534","doi":"10.25251/skin.5.supp.18","title":"Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; European Academy of Dermatology and Venereology","keywords":"Post-hoc analysis; Scalp; Medicine; Dermatology; Nail (fastener); Psoriasis; Post hoc; Dentistry; Internal medicine; Structural engineering; Engineering","authors":[{"name":"KA Papp","is_ca":true},{"name":"Mark Lebwohl","is_ca":false},{"name":"A.B. Gottlieb","is_ca":false},{"name":"Michael Sebastian","is_ca":false},{"name":"Richard G. Langley","is_ca":true},{"name":"Yukari Okubo","is_ca":false},{"name":"M Wang","is_ca":false},{"name":"Christopher L. Cioffi","is_ca":false},{"name":"Fabienne Staelens","is_ca":false},{"name":"Kristian Reich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02446779732439922,"gpt":0.2752013117497734,"spread":0.2507335144253741,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002980762,0.0009520153,0.002924683,0.0001993281,0.0003266858,0.001249569,0.0006402062,0.000881075,0.005303279],"category_scores_gemma":[0.001919703,0.0004516149,0.003061173,0.0003057063,0.0004427166,0.0009982289,0.0003916382,0.003465662,0.0007991681],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005350283,"about_ca_system_score_gemma":0.0008526825,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008929023,"about_ca_topic_score_gemma":0.002307867,"domain_scores_codex":[0.9991009,0.000511379,0.00003665888,0.0001150762,0.0000600875,0.0001757674],"domain_scores_gemma":[0.9989373,0.0004313937,0.0001811248,0.0001257166,0.0000676952,0.0002568328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9673456,0.001750633,0.001410464,0.0006926719,0.003454387,0.00004066472,0.00004649907,0.0008399102,0.002280154,0.0001378667,0.001932944,0.02006819],"study_design_scores_gemma":[0.8824946,0.08964843,0.01731541,0.0001357507,0.004672546,0.0001347735,0.00006602332,0.001423113,0.0008152081,0.0006274576,0.002631205,0.00003552972],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.978741,0.0113043,0.0009156661,0.0008607602,0.0004201019,0.001027681,0.002255105,0.0001145203,0.004360896],"genre_scores_gemma":[0.9895003,0.002693322,0.0008827384,0.0007624656,0.000251345,0.0008305282,0.001610562,0.00004316108,0.00342549],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005303279,"threshold_uncertainty_score":0.01774126,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3211628515","doi":"10.25251/skin.5.supp.42","title":"Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"","keywords":"Roflumilast; Dermis; Psoriasis; Medicine; Pharmacology; Phosphodiesterase inhibitor; Dermatology; Internal medicine; Pathology","authors":[{"name":"Mark Lebwohl","is_ca":false},{"name":"Leon Kircik","is_ca":false},{"name":"Angela Moore","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"J.Q. Del Rosso","is_ca":false},{"name":"Zoe Diana Draelos","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Lawrence Green","is_ca":false},{"name":"Adelaide A Herbert","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"Jerry Bagel","is_ca":false},{"name":"Neal Bhatia","is_ca":false},{"name":"Laura K. Ferris","is_ca":false},{"name":"Terry M. Jones","is_ca":false},{"name":"Steve Kempers","is_ca":false},{"name":"David M. Pariser","is_ca":false},{"name":"Paul S. Yamauchi","is_ca":false},{"name":"Matthew Zirwas","is_ca":false},{"name":"Amy Feng","is_ca":false},{"name":"Patrick Burnett","is_ca":false},{"name":"Robert Higham","is_ca":false},{"name":"David R. Berk","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01646162550159773,"gpt":0.301729772481566,"spread":0.2852681469799683,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007728759,0.0004840409,0.0008454609,0.0002574135,0.000331063,0.0003883731,0.0003204315,0.0006836193,0.009687566],"category_scores_gemma":[0.0004440744,0.0001856616,0.0006800033,0.0001643471,0.0002455942,0.0003710517,0.0001353151,0.001307111,0.001547021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003410926,"about_ca_system_score_gemma":0.0005380248,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008401874,"about_ca_topic_score_gemma":0.00283178,"domain_scores_codex":[0.9997665,0.00009895596,0.00001218296,0.00003224183,0.00003810089,0.00005204234],"domain_scores_gemma":[0.9998088,0.0000433273,0.00003475502,0.00002043877,0.00002512228,0.00006751541],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2978202,0.01789833,0.001715629,0.002125705,0.001221483,0.0003043517,0.00008949757,0.0008510337,0.1462298,0.001059086,0.03405186,0.4966331],"study_design_scores_gemma":[0.5022737,0.361107,0.01993853,0.0003790321,0.001149339,0.001133212,0.00007911962,0.001724885,0.03661013,0.001140325,0.07440832,0.00005642375],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8733304,0.03312659,0.005999329,0.004819521,0.00172751,0.006752136,0.007105618,0.001345773,0.06579323],"genre_scores_gemma":[0.9587799,0.009309347,0.00264677,0.001768403,0.0003450681,0.001651889,0.003014472,0.00007600603,0.02240807],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009687566,"threshold_uncertainty_score":0.03240818,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3107702560","doi":"10.25251/skin.4.supp.28","title":"BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Fungal Biology and Applications","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Psoriasis; Medicine; Internal medicine; Tyrosine-kinase inhibitor; Tyrosine kinase 2; Pharmacology; Dermatology; Platelet-derived growth factor receptor; Receptor","authors":[{"name":"Kenneth B. Gordon","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"Melinda Gooderham","is_ca":true},{"name":"Akimichi Morita","is_ca":false},{"name":"Peter Foley","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"Sundeep Kundu","is_ca":false},{"name":"Renata M. Kisa","is_ca":false},{"name":"Lan Wei","is_ca":false},{"name":"Subhashis Banergee","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04346348799405544,"gpt":0.3554140720406386,"spread":0.3119505840465832,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00115992,0.001091356,0.001655349,0.0003486824,0.0003263658,0.0007409768,0.0004951825,0.00103343,0.004996983],"category_scores_gemma":[0.0006270091,0.0003642772,0.001053952,0.0004604703,0.0005292781,0.000779914,0.0002199769,0.00265592,0.0008518013],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004422879,"about_ca_system_score_gemma":0.0008011524,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006912744,"about_ca_topic_score_gemma":0.00193866,"domain_scores_codex":[0.9997292,0.0001214116,0.00001926729,0.0000410169,0.00003540234,0.00005369715],"domain_scores_gemma":[0.9996087,0.0000842877,0.00006569192,0.0000231986,0.00002775834,0.000190405],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7872803,0.02588743,0.003564582,0.001515354,0.001670117,0.0003297024,0.0001296066,0.001421788,0.04305965,0.0002470371,0.005094232,0.1298003],"study_design_scores_gemma":[0.708672,0.2681144,0.01328111,0.00006938636,0.0006730993,0.0003291182,0.00005481799,0.001182306,0.004668516,0.00016178,0.002761115,0.00003228677],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823815,0.008786598,0.0004540393,0.0009351697,0.000264344,0.001574475,0.00157685,0.0001719719,0.003855034],"genre_scores_gemma":[0.9853222,0.005852409,0.001124827,0.001048139,0.0003417934,0.001331528,0.002188997,0.00002544581,0.002764684],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004996983,"threshold_uncertainty_score":0.0167166,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3102280768","doi":"10.25251/skin.4.supp.96","title":"Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Université Laval; Probity Medical Research; University of Toronto","funders":"","keywords":"Atopic dermatitis; Medicine; Dermatology; Phase (matter); Physics","authors":[{"name":"Eric L. Simpson","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Emma Guttman‐Yassky","is_ca":false},{"name":"Margitta Worm","is_ca":false},{"name":"Charles Lynde","is_ca":true},{"name":"Hidehisa Saeki","is_ca":false},{"name":"Yves Poulin","is_ca":true},{"name":"Andreas Wollenberg","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01976814871375346,"gpt":0.28888757321425,"spread":0.2691194245004965,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001842558,0.0009020203,0.001575234,0.0002393991,0.0003692773,0.0008773792,0.0005420911,0.00113166,0.002733057],"category_scores_gemma":[0.00113806,0.0003518669,0.001743908,0.0002685284,0.0004904888,0.0008196922,0.0001653015,0.002310375,0.0007313999],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005808408,"about_ca_system_score_gemma":0.0006893398,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008154036,"about_ca_topic_score_gemma":0.002836082,"domain_scores_codex":[0.9995696,0.0001782122,0.00004063281,0.00007603272,0.00005812743,0.00007735278],"domain_scores_gemma":[0.9991995,0.0002179479,0.0002101529,0.00006411308,0.00007216054,0.0002362578],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7220711,0.01681011,0.01074572,0.002925134,0.005068228,0.0003100737,0.0004049287,0.001998673,0.05661083,0.0001591848,0.005958827,0.1769372],"study_design_scores_gemma":[0.6045845,0.2969367,0.08420981,0.000197889,0.002736798,0.0008905305,0.000124134,0.001361318,0.004707479,0.0001895662,0.003975925,0.00008540621],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9827605,0.01264939,0.0002888686,0.0005512258,0.0001188011,0.0005778507,0.001301201,0.00009241956,0.001659776],"genre_scores_gemma":[0.9917901,0.00385278,0.0006853643,0.000709186,0.000151603,0.0003736827,0.00130649,0.00001818034,0.001112717],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002733057,"threshold_uncertainty_score":0.009744525,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3121057262","doi":"10.25251/skin.5.supp.3","title":"Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs)","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Basal cell carcinoma; Interim; Vismodegib; Internal medicine; Oncology; Medicine; Interim analysis; Basal cell; Clinical trial; History","authors":[{"name":"Karl D. Lewis","is_ca":false},{"name":"K. Peris","is_ca":false},{"name":"Aleksandar Sekulić","is_ca":false},{"name":"Alexander Stratigos","is_ca":false},{"name":"Lara Dunn","is_ca":false},{"name":"Zeynep Eroglu","is_ca":false},{"name":"Anne Lynn S. Chang","is_ca":false},{"name":"Michael R. Migden","is_ca":false},{"name":"Siyu Li","is_ca":false},{"name":"Suk‐Young Yoo","is_ca":false},{"name":"Kosalai Kal Mohan","is_ca":false},{"name":"Ebony Coates","is_ca":false},{"name":"Emmanuel Chiebuka Okoye","is_ca":false},{"name":"Jean‐François Baurain","is_ca":false},{"name":"Oliver Bechter","is_ca":false},{"name":"Axel Hauschild","is_ca":false},{"name":"Marcus O. Butler","is_ca":true},{"name":"Leonel F. Hernandez‐Aya","is_ca":false},{"name":"Lisa Licitra","is_ca":false},{"name":"Rogerio I. Neves","is_ca":false},{"name":"E.P. Yanez Ruiz","is_ca":false},{"name":"Frank Seebach","is_ca":false},{"name":"Israel Lowy","is_ca":false},{"name":"Timothy G. Bowler","is_ca":false},{"name":"Matthew G. Fury","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01888602988988578,"gpt":0.2952838839229059,"spread":0.2763978540330201,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006770986,0.001414536,0.002481957,0.0003914651,0.0005128598,0.001951018,0.0006701825,0.001281196,0.005768141],"category_scores_gemma":[0.004363612,0.0004665195,0.003219464,0.0004474118,0.0005434852,0.00128853,0.0004941855,0.003460527,0.001073513],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009549846,"about_ca_system_score_gemma":0.001364566,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004143321,"about_ca_topic_score_gemma":0.001467981,"domain_scores_codex":[0.9980382,0.001169797,0.00008094083,0.000150309,0.0001414748,0.0004192954],"domain_scores_gemma":[0.9973511,0.0009904595,0.0005490422,0.0003052572,0.00014422,0.0006599538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.876623,0.004881133,0.0134871,0.0007787299,0.004169203,0.0003362632,0.0001609572,0.006291519,0.009681497,0.0005747555,0.01312549,0.06989045],"study_design_scores_gemma":[0.4758509,0.3787997,0.09857503,0.0002629787,0.006730678,0.0009240982,0.000238927,0.007500871,0.0087709,0.003169282,0.019042,0.0001347197],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9531235,0.008416455,0.00359782,0.002503643,0.0007849182,0.004294375,0.01488149,0.0003193253,0.01207853],"genre_scores_gemma":[0.9712248,0.0015086,0.003046038,0.002443037,0.0002970299,0.004292173,0.0120414,0.0001120072,0.005035016],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006770986,"threshold_uncertainty_score":0.0358088,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4309315772","doi":"10.25251/skin.6.6.5","title":"A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients with High-Risk Cutaneous Squamous Cell Carcinoma (cSCC)","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Internal medicine; Oncology; Risk assessment; Prospective cohort study; Population; Incidence (geometry); Personalized medicine; Intensive care medicine; Bioinformatics; Environmental health","authors":[{"name":"Eli Saleeby","is_ca":false},{"name":"Kenneth Bielinski","is_ca":true},{"name":"Alison L. Fitzgerald","is_ca":false},{"name":"Jennifer J. Siegel","is_ca":false},{"name":"Sherrif F. Ibrahim","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02762869602684959,"gpt":0.3193341928845215,"spread":0.2917054968576719,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002495565,0.0002049807,0.0001823151,0.0005608834,0.0004337651,0.0007942701,0.0002370325,0.0003028983,0.001271859],"category_scores_gemma":[0.00713016,0.0001795234,0.0003039785,0.000657185,0.0004511038,0.0006142234,0.0007671071,0.0005054799,0.0002410277],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004811795,"about_ca_system_score_gemma":0.0005301905,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003270969,"about_ca_topic_score_gemma":0.003881225,"domain_scores_codex":[0.9986419,0.0006039047,0.0001107808,0.0002450718,0.0002380113,0.0001603303],"domain_scores_gemma":[0.9942668,0.001764016,0.002272122,0.0004377603,0.0004155194,0.0008437607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003716694,0.0001449226,0.9966326,0.000003577809,0.00003693517,0.00004274901,0.00007617311,0.000042189,0.0001732701,0.00001550113,0.0001099584,0.002350296],"study_design_scores_gemma":[0.00003384138,0.0006484175,0.9983476,0.00000262277,0.00002769,0.0001571321,0.0001363672,0.000289381,0.0001447871,0.00001925313,0.0001890852,0.000003699779],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9994659,0.00005069733,0.00007214386,0.00003657733,0.000001553995,0.00001043415,0.0001233351,0.000002353542,0.0002369412],"genre_scores_gemma":[0.9996164,0.00002673185,0.00008902734,0.0000520312,0.000005259177,0.000007802392,0.000125778,0.000001092213,0.00007575536],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003270969,"threshold_uncertainty_score":0.01319802,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3213252676","doi":"10.25251/skin.5.supp.37","title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Apremilast; Placebo; Psoriasis; Medicine; Internal medicine; Pharmacology; Dermatology; Psoriatic arthritis; Alternative medicine; Pathology","authors":[{"name":"Diamant Thaçi","is_ca":false},{"name":"Kenneth B. Gordon","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Bruce Strober","is_ca":false},{"name":"Neil J. Korman","is_ca":false},{"name":"Subhashis Banerjee","is_ca":false},{"name":"Subhashis Banerjee","is_ca":false},{"name":"Elizabeth Colston","is_ca":false},{"name":"Jonghyeon Kim","is_ca":false},{"name":"John Throup","is_ca":false},{"name":"Akimichi Morita","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0246529517252897,"gpt":0.2993854296567134,"spread":0.2747324779314237,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001268722,0.0007089485,0.002306164,0.0002664954,0.000199535,0.0007719278,0.0004332204,0.0006800487,0.004123165],"category_scores_gemma":[0.00110477,0.0002418673,0.001513409,0.0002921673,0.0003707144,0.0007595891,0.0001911783,0.001548712,0.0005311759],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004932257,"about_ca_system_score_gemma":0.0005151589,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007766467,"about_ca_topic_score_gemma":0.002405837,"domain_scores_codex":[0.9995137,0.0002494511,0.00004534048,0.00006724677,0.00005841598,0.00006574678],"domain_scores_gemma":[0.9994041,0.0002015116,0.0001584675,0.00003269563,0.00003996889,0.00016338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8929567,0.002613622,0.00130341,0.001298723,0.002443474,0.00003545759,0.00003312944,0.0005059228,0.00921832,0.00008604662,0.002183272,0.08732185],"study_design_scores_gemma":[0.7461728,0.21104,0.02679948,0.0002107056,0.004811218,0.0002855649,0.00008189728,0.001462341,0.004387115,0.0003098722,0.004387318,0.00005157252],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9539288,0.03643141,0.0006352387,0.0009495211,0.0004541773,0.0006561503,0.002009599,0.0001962035,0.004738842],"genre_scores_gemma":[0.9859189,0.008703038,0.0006114438,0.0005615081,0.0002804855,0.0003289155,0.001450848,0.00002093432,0.002124029],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004123165,"threshold_uncertainty_score":0.01379329,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3104685239","doi":"10.25251/skin.4.supp.93","title":"The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Innovaderm (Canada); Probity Medical Research; Queen's University","funders":"","keywords":"Atopic dermatitis; Roflumilast; Proof of concept; Medicine; Dermatology; Computer science; Internal medicine","authors":[{"name":"Melinda Gooderham","is_ca":true},{"name":"Leon Kircik","is_ca":false},{"name":"Matthew Zirwas","is_ca":false},{"name":"Mark Lee","is_ca":false},{"name":"Steven Kempers","is_ca":false},{"name":"Zoe Diana Draelos","is_ca":false},{"name":"Laura K. Ferris","is_ca":false},{"name":"Terry M. Jones","is_ca":false},{"name":"Étienne Saint‐Cyr Proulx","is_ca":true},{"name":"Robert Bissonnette","is_ca":true},{"name":"Neal Bhatia","is_ca":false},{"name":"Scott Guenthner","is_ca":false},{"name":"Robert A. Koppel","is_ca":false},{"name":"Howard G. Welgus","is_ca":false},{"name":"Charlotte Merritt","is_ca":false},{"name":"M.E.M. Elias","is_ca":false},{"name":"Lynn Navale","is_ca":false},{"name":"Robert Higham","is_ca":false},{"name":"Michael Droege","is_ca":false},{"name":"David R. Berk","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01259036974305243,"gpt":0.2879166144450862,"spread":0.2753262447020338,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00286155,0.001796032,0.002527138,0.0004340374,0.0004363292,0.001433083,0.001392403,0.001695647,0.007179512],"category_scores_gemma":[0.001345162,0.0008974851,0.002150343,0.0003582433,0.001159839,0.00141344,0.0003288826,0.004178675,0.001692898],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000734708,"about_ca_system_score_gemma":0.001707896,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006449906,"about_ca_topic_score_gemma":0.001411238,"domain_scores_codex":[0.9992362,0.0003517948,0.0000425689,0.0001202351,0.0001033061,0.0001460035],"domain_scores_gemma":[0.9991559,0.0002513372,0.000159824,0.0001166335,0.00009854698,0.0002178028],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6051555,0.129661,0.0008997092,0.005572935,0.002075763,0.0003337668,0.000392469,0.001440651,0.140679,0.0006215905,0.005852036,0.1073157],"study_design_scores_gemma":[0.3050886,0.669199,0.004166768,0.0001648991,0.0009765787,0.0003192921,0.00010631,0.0008033332,0.01216208,0.0003038444,0.006654607,0.00005459238],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9658486,0.01418582,0.002892686,0.0009557077,0.0008342045,0.008859785,0.002612588,0.0003020673,0.003508567],"genre_scores_gemma":[0.9678603,0.009845781,0.005343337,0.001405505,0.0005358094,0.00701261,0.002182445,0.00008767092,0.005726515],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007179512,"threshold_uncertainty_score":0.02401781,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388626054","doi":"10.25251/skin.7.supp.291","title":"Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Alopecia areata; Phase (matter); Dermatology; Medicine; Chemistry; Organic chemistry","authors":[{"name":"Brett King","is_ca":false},{"name":"Jennifer Soung","is_ca":false},{"name":"Christos Tziotzios","is_ca":false},{"name":"Lidia Rudnicka","is_ca":false},{"name":"P. Joly","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Rodney Sinclair","is_ca":false},{"name":"Susan D. Anway","is_ca":false},{"name":"Dalia Wajsbrot","is_ca":false},{"name":"Alexandre Lejeune","is_ca":false},{"name":"Samuel H. Zwillich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08132641213904793,"gpt":0.4348392751947991,"spread":0.3535128630557511,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009266319,0.0012139,0.002267443,0.00121718,0.0006100045,0.002065133,0.0008272818,0.001478273,0.01003502],"category_scores_gemma":[0.005173154,0.0005392226,0.004792573,0.0009758482,0.0004147249,0.001059116,0.001000691,0.001910503,0.001015913],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001082754,"about_ca_system_score_gemma":0.002934998,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006332808,"about_ca_topic_score_gemma":0.002472422,"domain_scores_codex":[0.9957588,0.002477063,0.0002847296,0.0004088829,0.0007614049,0.0003090265],"domain_scores_gemma":[0.9968631,0.0008776273,0.001076449,0.0002346869,0.0005262467,0.0004220201],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.666626,0.007244369,0.0211509,0.01127105,0.03370376,0.0004953414,0.0004108375,0.003745575,0.02332114,0.001146247,0.02759235,0.2032924],"study_design_scores_gemma":[0.5799936,0.1661908,0.110154,0.00233352,0.04501339,0.001304562,0.0002517371,0.002852448,0.00860035,0.001862226,0.08123219,0.0002111563],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8061053,0.04982499,0.007046453,0.003566132,0.0004515313,0.04594265,0.06447299,0.000680619,0.02190931],"genre_scores_gemma":[0.8807061,0.01644962,0.009428374,0.004992759,0.0006158321,0.03078312,0.04832015,0.000206536,0.008497413],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01003502,"threshold_uncertainty_score":0.04900557,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2993441120","doi":"10.25251/skin.3.6.2","title":"Transitioning Between Biologics","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Adverse effect; Intensive care medicine; Biologic Agents; Plaque psoriasis; Psoriasis; Internal medicine; Dermatology; Disease","authors":[{"name":"Ronald Vender","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01464011930249902,"gpt":0.2405203201935189,"spread":0.2258802008910199,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003491463,0.0003228385,0.0007937367,0.000834539,0.0005434213,0.001715551,0.0008803324,0.001311957,0.009197526],"category_scores_gemma":[0.01031028,0.0002219808,0.001437009,0.0005230323,0.0006466417,0.002238953,0.001030115,0.003533013,0.002909448],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007105393,"about_ca_system_score_gemma":0.00109323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005195331,"about_ca_topic_score_gemma":0.0006832324,"domain_scores_codex":[0.9972433,0.0009890725,0.0004962274,0.0003891205,0.0006919539,0.000190375],"domain_scores_gemma":[0.9943833,0.002699343,0.00143669,0.0003869335,0.0006349645,0.0004586563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002383611,0.00104585,0.004886854,0.006782057,0.0002689571,0.0008530351,0.0005837721,0.0003525069,0.006084968,0.005998007,0.02017023,0.9505901],"study_design_scores_gemma":[0.001544741,0.006582984,0.01312658,0.01041349,0.001287697,0.008145449,0.001210107,0.0005980297,0.01289499,0.01940287,0.9246814,0.0001117424],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1351819,0.6878622,0.03564318,0.03525047,0.006014586,0.001774911,0.0009328441,0.001141471,0.09619852],"genre_scores_gemma":[0.6485152,0.2307805,0.0541169,0.03967915,0.003936498,0.001223061,0.001205769,0.000249363,0.02029357],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.009197526,"threshold_uncertainty_score":0.03076881,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2789068895","doi":"10.25251/skin.2.supp.4","title":"Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Term (time); Dermatology; Clinical efficacy; Internal medicine; Physics","authors":[{"name":"Kim Papp","is_ca":true},{"name":"Kristian Reich","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"Rodney Sinclair","is_ca":false},{"name":"Stephen K. Tyring","is_ca":false},{"name":"N. Cichanowitz","is_ca":false},{"name":"Stuart A. Green","is_ca":false},{"name":"Qing Li","is_ca":false},{"name":"Carmen La Rosa","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04899517628077045,"gpt":0.3759920803540572,"spread":0.3269969040732868,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003256151,0.001064239,0.00226972,0.0004317379,0.000542147,0.0009161492,0.000444113,0.001303352,0.002534528],"category_scores_gemma":[0.001644169,0.0003798268,0.002030929,0.0004693063,0.0006238626,0.0009156426,0.000281224,0.00208375,0.000601162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006773943,"about_ca_system_score_gemma":0.0008372906,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00139197,"about_ca_topic_score_gemma":0.003118463,"domain_scores_codex":[0.9989743,0.0004610887,0.00006492221,0.0001363637,0.0001486118,0.0002146661],"domain_scores_gemma":[0.9986866,0.0003092885,0.0003640304,0.0001145198,0.0001097715,0.0004158099],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6984867,0.02794851,0.0212201,0.00174953,0.005432903,0.0003278563,0.0003830066,0.001101382,0.03003797,0.0001396838,0.003511768,0.2096605],"study_design_scores_gemma":[0.4382498,0.4126935,0.1385116,0.0002751902,0.00286408,0.0005003024,0.0001359969,0.0006661598,0.001928362,0.0001919772,0.003916054,0.00006706118],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9756376,0.0196116,0.0002666536,0.0004427016,0.0001651139,0.0007681802,0.0008093553,0.00007030175,0.002228396],"genre_scores_gemma":[0.9899351,0.005682393,0.000414141,0.0007389772,0.0002771254,0.0005425521,0.001082904,0.00001528841,0.001311504],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003256151,"threshold_uncertainty_score":0.01722044,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3103727622","doi":"10.25251/skin.4.supp.83","title":"Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"","keywords":"Double blinded; Medicine; Randomized controlled trial; Placebo; Plaque psoriasis; Psoriasis; Internal medicine; Dermatology; Alternative medicine; Pathology","authors":[{"name":"Kenneth B. Gordon","is_ca":false},{"name":"Peter Foley","is_ca":false},{"name":"JG Krueger","is_ca":false},{"name":"Andreas Pinter","is_ca":false},{"name":"Kristian Reich","is_ca":false},{"name":"Ronald Vender","is_ca":true},{"name":"Veerle Vanvoorden","is_ca":false},{"name":"Cindy Madden","is_ca":false},{"name":"Luke Peterson","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01612960875211718,"gpt":0.2519932776894991,"spread":0.235863668937382,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002742321,0.001102942,0.003838022,0.0003963671,0.0006444425,0.001217288,0.0008214817,0.002244381,0.005415265],"category_scores_gemma":[0.002169327,0.00079837,0.002361489,0.0003626171,0.001335091,0.001442863,0.0004050757,0.00366304,0.001035899],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004227629,"about_ca_system_score_gemma":0.0008848727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005068881,"about_ca_topic_score_gemma":0.000908591,"domain_scores_codex":[0.9991078,0.0004527543,0.00006456114,0.0001280803,0.0001022566,0.0001445076],"domain_scores_gemma":[0.9987004,0.0004121489,0.0002893728,0.000131132,0.00009447292,0.0003723358],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9556406,0.007326066,0.0007636426,0.0008979152,0.0008503885,0.00004011655,0.00006093043,0.0002058266,0.006281197,0.0000879496,0.0008660291,0.02697943],"study_design_scores_gemma":[0.9131942,0.08172454,0.003161744,0.0000463088,0.0004302783,0.00004400917,0.00002410566,0.0001906675,0.0005631836,0.0001243555,0.000480153,0.00001640826],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9784437,0.01296036,0.0009414945,0.000885829,0.00048536,0.002659939,0.001070493,0.0001594295,0.002393379],"genre_scores_gemma":[0.9886445,0.003461457,0.001475224,0.001442499,0.0004992346,0.00190211,0.0007595703,0.00003800471,0.001777437],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005415265,"threshold_uncertainty_score":0.01811588,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4229034592","doi":"10.25251/skin.6.supp.4","title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Medicine; Psoriasis; Internal medicine; Pharmacology; Dermatology","authors":[{"name":"Richard B. Warren","is_ca":false},{"name":"April W. Armstrong","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Bruce Strober","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"Shinichi Imafuku","is_ca":false},{"name":"Howard Sofen","is_ca":false},{"name":"Lynda Spelman","is_ca":false},{"name":"Neil J. Korman","is_ca":false},{"name":"Min Zheng","is_ca":false},{"name":"Elizabeth Colston","is_ca":false},{"name":"John Throup","is_ca":false},{"name":"Sundeep Kundu","is_ca":false},{"name":"Renata M. Kisa","is_ca":false},{"name":"Subhashis Banerjee","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04009431060346913,"gpt":0.302258072534325,"spread":0.2621637619308559,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001134721,0.0006360066,0.001575322,0.0001942956,0.0002893539,0.0007111335,0.0003507063,0.0005841177,0.002648554],"category_scores_gemma":[0.0004661895,0.0002174675,0.001029072,0.0001869055,0.0003423834,0.0005109568,0.0001687298,0.001710144,0.0006275869],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004665398,"about_ca_system_score_gemma":0.0004535483,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008880469,"about_ca_topic_score_gemma":0.003341989,"domain_scores_codex":[0.9997382,0.00008963106,0.00001775866,0.00004048377,0.000047818,0.00006618485],"domain_scores_gemma":[0.9996556,0.00008345292,0.00006864963,0.00002715214,0.00002891538,0.000136207],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3770461,0.01372266,0.005181973,0.002221765,0.002401593,0.0002933722,0.0001819365,0.00280836,0.07549442,0.0003418987,0.01895005,0.5013559],"study_design_scores_gemma":[0.5100907,0.358111,0.07497375,0.0002954931,0.002479135,0.00177955,0.0001716958,0.004017463,0.02298894,0.0007276112,0.02422694,0.0001376811],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9650593,0.02427244,0.0009354498,0.001011294,0.0002332666,0.0005817387,0.001556557,0.0002891305,0.00606081],"genre_scores_gemma":[0.9824321,0.009287119,0.000764743,0.000813823,0.0001648556,0.0002832977,0.002296216,0.00004459613,0.003913285],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002648554,"threshold_uncertainty_score":0.00886035,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2989489239","doi":"10.25251/skin.3.supp.17","title":"Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"","keywords":"Phase (matter); Medicine; Physics","authors":[{"name":"C.E.M. Griffiths","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"Mengsa Song","is_ca":false},{"name":"Megan Miller","is_ca":false},{"name":"Yin You","is_ca":false},{"name":"Y-K Shen","is_ca":false},{"name":"Chenglong Han","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01294236937267002,"gpt":0.3188810422485794,"spread":0.3059386728759094,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002117189,0.000820392,0.002341436,0.0002567517,0.0004748287,0.001427158,0.0007761539,0.001400012,0.004896489],"category_scores_gemma":[0.001525953,0.000255811,0.002357868,0.0003873962,0.000785955,0.001704337,0.0004155576,0.00407418,0.001098676],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008512517,"about_ca_system_score_gemma":0.0007154625,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007226514,"about_ca_topic_score_gemma":0.001710095,"domain_scores_codex":[0.9994085,0.0002346045,0.00002414678,0.00009619248,0.00004849609,0.0001880201],"domain_scores_gemma":[0.9984713,0.0004572967,0.0003086594,0.0002107083,0.0000759875,0.0004761037],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7626749,0.007369186,0.004248341,0.001785234,0.003824584,0.0001462721,0.0002290114,0.002050036,0.01183639,0.0004651443,0.007692028,0.1976789],"study_design_scores_gemma":[0.7498481,0.1861152,0.04746896,0.0004854978,0.002215297,0.0004603405,0.0001553405,0.001451628,0.002467977,0.001260051,0.007994294,0.00007728999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.96786,0.0218114,0.0008370243,0.001624687,0.0005030338,0.0007605521,0.002151196,0.0002069674,0.004245198],"genre_scores_gemma":[0.987145,0.004296369,0.0008355767,0.00158717,0.0002332752,0.0007567984,0.002322286,0.0000551167,0.002768514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004896489,"threshold_uncertainty_score":0.01638037,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3213919372","doi":"10.25251/skin.5.supp.44","title":"Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Roflumilast; Open label; Plaque psoriasis; Medicine; Psoriasis; Dermatology; Adverse effect; Term (time); Pharmacology; Internal medicine; COPD","authors":[{"name":"Linda Stein Gold","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Kim Papp","is_ca":true},{"name":"Laura K. Ferris","is_ca":false},{"name":"Mark Lebwohl","is_ca":false},{"name":"David N. Adam","is_ca":true},{"name":"Javier Alonso‐Llamazares","is_ca":false},{"name":"Chih-ho Hong","is_ca":true},{"name":"Steve Kempers","is_ca":false},{"name":"Leon Kircik","is_ca":false},{"name":"Wei Jing Loo","is_ca":false},{"name":"Daniel Stewart","is_ca":false},{"name":"Walter K. Nahm","is_ca":false},{"name":"Matthew Zirwas","is_ca":false},{"name":"Patrick Burnett","is_ca":false},{"name":"Robert Higham","is_ca":false},{"name":"Lynn Navale","is_ca":false},{"name":"David R. Berk","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0163068083733599,"gpt":0.2737719592662977,"spread":0.2574651508929378,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00179226,0.001176417,0.002526654,0.0003357285,0.0004091741,0.0007925338,0.0006418383,0.001534632,0.00277466],"category_scores_gemma":[0.001112055,0.0005549248,0.001398448,0.0003303967,0.0008880562,0.001013088,0.0002387813,0.002250398,0.0009656193],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000419834,"about_ca_system_score_gemma":0.0005653395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006372748,"about_ca_topic_score_gemma":0.001125357,"domain_scores_codex":[0.9993529,0.0002807888,0.00005330846,0.0001084777,0.00008841851,0.0001162484],"domain_scores_gemma":[0.9991758,0.0002203508,0.0002149986,0.00009885092,0.00007088183,0.0002190194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7944694,0.03764188,0.006547584,0.001177092,0.001553717,0.0002931896,0.0002459331,0.000859551,0.05537327,0.00009599647,0.001863371,0.09987909],"study_design_scores_gemma":[0.482224,0.4666659,0.04281377,0.00007679599,0.001096028,0.0004000429,0.00009845587,0.0007610109,0.003716611,0.0001229749,0.001962502,0.00006189161],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931138,0.004180766,0.0003931315,0.000207451,0.00006869447,0.0005397192,0.0005596009,0.00007097828,0.0008657462],"genre_scores_gemma":[0.9923536,0.002762485,0.0006889641,0.0006666098,0.0002550156,0.00067793,0.00104004,0.00002489297,0.001530431],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00277466,"threshold_uncertainty_score":0.009478509,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2986283446","doi":"10.25251/skin.3.supp.38","title":"Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Nail (fastener); Dermatology; Outcome (game theory); Internal medicine; Infliximab; Tumor necrosis factor alpha; Materials science","authors":[{"name":"Alice B. Gottlieb","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"C. Leonardi","is_ca":false},{"name":"Yves Poulin","is_ca":true},{"name":"Sarah Kavanagh","is_ca":false},{"name":"Marion Boehnlein","is_ca":false},{"name":"Kristian Reich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03094004696178332,"gpt":0.2977013145001826,"spread":0.2667612675383993,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016899,0.0006336204,0.001502165,0.0002109979,0.0002452495,0.0007604727,0.0003544723,0.0007920382,0.004826235],"category_scores_gemma":[0.001625239,0.0001615301,0.00185656,0.0002810192,0.0003782165,0.0004994203,0.0002007676,0.001830505,0.0005656888],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004451355,"about_ca_system_score_gemma":0.0004674967,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008117587,"about_ca_topic_score_gemma":0.001997605,"domain_scores_codex":[0.9995189,0.0002204382,0.00003398846,0.00006100968,0.00007840749,0.00008732369],"domain_scores_gemma":[0.9991241,0.0003927982,0.0001982086,0.00004767297,0.00008955192,0.0001476397],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5045062,0.006064697,0.004742987,0.01222479,0.00914214,0.0002068013,0.0001643475,0.001295287,0.01343781,0.0005146006,0.0164961,0.4312043],"study_design_scores_gemma":[0.7205676,0.1746321,0.06171346,0.003245484,0.01024537,0.000765346,0.0002365536,0.001432067,0.004586043,0.002215048,0.02028191,0.00007891638],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7530582,0.2183189,0.001711581,0.005067823,0.001118655,0.002538283,0.003301515,0.0003464929,0.01453863],"genre_scores_gemma":[0.9535778,0.03655476,0.001232086,0.003080611,0.0005352936,0.0008128764,0.001337673,0.00002783315,0.0028411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004826235,"threshold_uncertainty_score":0.01614541,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3213641793","doi":"10.25251/skin.5.supp.62","title":"Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Innovaderm (Canada)","funders":"LEO Pharma; EMD Serono; Bausch Health; Glenmark Pharmaceuticals; Sanofi Genzyme; Incyte; Dermira; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Atopic dermatitis; Medicine; Dermatology","authors":[{"name":"Lawrence Eichenfeld","is_ca":false},{"name":"Jonathan I. Silverberg","is_ca":false},{"name":"Robert Bissonnette","is_ca":true},{"name":"Anna M. Tallman","is_ca":false},{"name":"David S. Rubenstein","is_ca":false},{"name":"Stephen C. Piscitelli","is_ca":false},{"name":"John E Jett","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0176862136550827,"gpt":0.3443466066119262,"spread":0.3266603929568435,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001305459,0.0007689705,0.001314742,0.0002788837,0.0004273843,0.0007377118,0.0007098997,0.001006788,0.00482251],"category_scores_gemma":[0.0006784455,0.0002949023,0.001046687,0.0002492976,0.0004575686,0.0004914848,0.0002461988,0.001960572,0.0007300026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005119157,"about_ca_system_score_gemma":0.001277339,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001501751,"about_ca_topic_score_gemma":0.004833961,"domain_scores_codex":[0.9997503,0.0001143906,0.00001340459,0.00003092465,0.0000334016,0.00005767648],"domain_scores_gemma":[0.9996247,0.00008089418,0.000058963,0.0000229285,0.0000518363,0.0001606574],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4162958,0.05685169,0.007359664,0.004153615,0.001802916,0.0004101623,0.000384031,0.001405995,0.04169409,0.001277746,0.03721482,0.4311494],"study_design_scores_gemma":[0.6812907,0.2604856,0.02206283,0.0005720567,0.00078939,0.0007164408,0.0001490021,0.0009699363,0.003514227,0.0004677842,0.02893758,0.00004460196],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9275148,0.03711933,0.00228498,0.003236896,0.0009863897,0.0106948,0.003860326,0.0002528711,0.01404973],"genre_scores_gemma":[0.9355171,0.03268513,0.007039148,0.004670638,0.0007475358,0.006080533,0.003758525,0.00008037755,0.009420967],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00482251,"threshold_uncertainty_score":0.01613295,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3102615618","doi":"10.25251/skin.4.supp.82","title":"Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; AstraZeneca","keywords":"Ustekinumab; Double blinded; Medicine; Placebo; Plaque psoriasis; Psoriasis; Dermatology; Randomized controlled trial; Internal medicine; Pathology; Disease; Alternative medicine","authors":[{"name":"Kristian Reich","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Richard G. Langley","is_ca":true},{"name":"April W. Armstrong","is_ca":false},{"name":"Richard B. Warren","is_ca":false},{"name":"Kenneth B. Gordon","is_ca":false},{"name":"J.F. Merola","is_ca":false},{"name":"Cindy Madden","is_ca":false},{"name":"M Wang","is_ca":false},{"name":"Veerle Vanvoorden","is_ca":false},{"name":"Mark Lebwohl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01981299134265906,"gpt":0.255535521771845,"spread":0.2357225304291859,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001900549,0.0007885747,0.002557053,0.0002450597,0.0003801077,0.0008635877,0.0006261235,0.00135212,0.002597054],"category_scores_gemma":[0.001523415,0.0005520544,0.001359034,0.0002574464,0.0006992362,0.0008737572,0.0002872882,0.002576597,0.000547329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000409295,"about_ca_system_score_gemma":0.000667981,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000461048,"about_ca_topic_score_gemma":0.0008385318,"domain_scores_codex":[0.9994492,0.000287699,0.00004031251,0.00007189759,0.00006895918,0.00008194394],"domain_scores_gemma":[0.9992531,0.0002229115,0.0001673295,0.00005913278,0.00004627755,0.000251309],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.897146,0.01027758,0.003992056,0.001375144,0.001831049,0.0001017791,0.0001284437,0.0006022372,0.01469243,0.0001782548,0.001909476,0.06776553],"study_design_scores_gemma":[0.8391411,0.1349102,0.02044794,0.00008258972,0.001040958,0.0002304024,0.00005833651,0.0007717229,0.001405245,0.0002770891,0.001602846,0.00003170739],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844862,0.01103723,0.000422947,0.0005688872,0.0001966676,0.0007427503,0.0005739325,0.00008008724,0.001891278],"genre_scores_gemma":[0.993826,0.00263569,0.000628828,0.0007761436,0.0002348406,0.0004667539,0.000551998,0.00001406215,0.0008657369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002597054,"threshold_uncertainty_score":0.01005119,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3119812808","doi":"10.25251/skin.5.supp.15","title":"Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; European Academy of Dermatology and Venereology","keywords":"Medicine; Adalimumab; Plaque psoriasis; Double blinded; Multicenter study; Randomized controlled trial; Psoriasis; Internal medicine; Dermatology; Pathology; Placebo; Alternative medicine","authors":[{"name":"Richard B. Warren","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Jerry Bagel","is_ca":false},{"name":"KA Papp","is_ca":true},{"name":"Paul S. Yamauchi","is_ca":false},{"name":"April W. Armstrong","is_ca":false},{"name":"Richard G. Langley","is_ca":true},{"name":"Veerle Vanvoorden","is_ca":false},{"name":"Dirk De Cuyper","is_ca":false},{"name":"Luke Peterson","is_ca":false},{"name":"Nancy Cross","is_ca":false},{"name":"Kristian Reich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02438267293933946,"gpt":0.2821770173124763,"spread":0.2577943443731369,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003158651,0.001222924,0.003668664,0.0003273729,0.000647035,0.001697562,0.0008400436,0.002152299,0.006677728],"category_scores_gemma":[0.002904644,0.0007596978,0.002689875,0.0003858252,0.001110551,0.001565612,0.0004641827,0.003450007,0.001075193],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005912044,"about_ca_system_score_gemma":0.0008160769,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005388185,"about_ca_topic_score_gemma":0.000888402,"domain_scores_codex":[0.9990496,0.0004762468,0.00007772529,0.0001834541,0.0000834316,0.0001294309],"domain_scores_gemma":[0.9985747,0.0004851524,0.0003664511,0.0001209827,0.00009632089,0.0003563695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9811762,0.002302458,0.0004757525,0.0006732722,0.001091886,0.00002133441,0.00003906755,0.0001414823,0.001835813,0.0000790175,0.000810837,0.0113529],"study_design_scores_gemma":[0.9683928,0.02790906,0.002024752,0.00004555834,0.0006183239,0.00003153682,0.0000160176,0.0001792711,0.0002106675,0.0001580964,0.0004013616,0.00001247542],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9702502,0.01819911,0.001000449,0.001497869,0.0009826289,0.00294325,0.001641682,0.0001851618,0.003299607],"genre_scores_gemma":[0.9852941,0.00375809,0.002155649,0.002039149,0.0009050912,0.002595693,0.001125878,0.00004974486,0.002076632],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006677728,"threshold_uncertainty_score":0.02233917,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3214549902","doi":"10.25251/skin.5.supp.38","title":"Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Psoriasis; Plaque psoriasis; Medicine; Domain (mathematical analysis); Dermatology; Mathematics; Mathematical analysis","authors":[{"name":"April W. Armstrong","is_ca":false},{"name":"Bruce Strober","is_ca":false},{"name":"Kenneth B. Gordon","is_ca":false},{"name":"Joe Zhuo","is_ca":false},{"name":"Brandon Becker","is_ca":false},{"name":"Renata M. Kisa","is_ca":false},{"name":"John Throup","is_ca":false},{"name":"Jonghyeon Kim","is_ca":false},{"name":"Kim Papp","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01256961024483013,"gpt":0.2492058804157619,"spread":0.2366362701709317,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007031973,0.0004205824,0.001222935,0.000142028,0.0001955796,0.0004469736,0.0002705276,0.0003853104,0.002500433],"category_scores_gemma":[0.0005600466,0.0001542036,0.0009887188,0.0001480978,0.0001925375,0.0003731112,0.0001116434,0.001017611,0.0003830872],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003586783,"about_ca_system_score_gemma":0.0003446778,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007656074,"about_ca_topic_score_gemma":0.00296471,"domain_scores_codex":[0.999765,0.00008926418,0.00002198572,0.00002994547,0.00004634251,0.0000475226],"domain_scores_gemma":[0.9996928,0.00008454864,0.00008587918,0.00002065993,0.00003558777,0.00008051162],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3308753,0.01209826,0.01373132,0.00266278,0.004387165,0.000197797,0.0001310731,0.001842764,0.05599901,0.0001710755,0.0140874,0.5638161],"study_design_scores_gemma":[0.3421811,0.3558112,0.2447053,0.0003352343,0.004590083,0.001832983,0.000199737,0.004015206,0.02142025,0.0004598938,0.02431395,0.0001350594],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9758747,0.018262,0.0003333506,0.0006358345,0.00016092,0.0002813432,0.0008183565,0.0001523074,0.003481277],"genre_scores_gemma":[0.9919568,0.005059625,0.0003649521,0.0004158592,0.00009035245,0.00008634417,0.000844555,0.00001397642,0.001167598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002500433,"threshold_uncertainty_score":0.008364797,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4390904689","doi":"10.25251/skin.8.supp.349","title":"Bimekizumab Efficacy by Prior Biologic Treatment in Patients with Moderate to Severe Hidradenitis Suppurativa: 48-Week Pooled Data from the Randomized, Double-Blind, Placebo-Controlled, Multicenter BE HEARD I and II Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Cilag; Genentech; LEO Pharma; Sanofi Genzyme; Incyte; National Eczema Association; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Biogen; Amgen; Pfizer; Galderma; Eli Lilly and Company; Sanofi","keywords":"Hidradenitis suppurativa; Medicine; Double blind; Placebo; Multicenter study; Pooled analysis; Internal medicine; Multicenter trial; Dermatology; Randomized controlled trial; Pathology; Alternative medicine; Meta-analysis; Disease","authors":[{"name":"Christopher J. Sayed","is_ca":false},{"name":"Vivian Y. Shi","is_ca":false},{"name":"Jennifer L. Hsiao","is_ca":false},{"name":"Georgios Kokolakis","is_ca":false},{"name":"Brian Kirby","is_ca":false},{"name":"Vincent Piguet","is_ca":true},{"name":"Leah Davis","is_ca":false},{"name":"Muhammad Bari","is_ca":false},{"name":"Cynthia Madden","is_ca":false},{"name":"Sarah Knowles","is_ca":false},{"name":"Errol P. Prens","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05229412364784481,"gpt":0.3412784765418269,"spread":0.2889843528939821,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00966309,0.001350257,0.005411576,0.0008913357,0.0004591575,0.001855752,0.0007323341,0.001794176,0.002965081],"category_scores_gemma":[0.009349682,0.0007022976,0.00821548,0.00101057,0.0007436628,0.001405718,0.0006377955,0.001997633,0.00032029],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005414601,"about_ca_system_score_gemma":0.0007543517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005894939,"about_ca_topic_score_gemma":0.001668768,"domain_scores_codex":[0.9947885,0.003042694,0.0008073843,0.0005380945,0.0005650374,0.000258286],"domain_scores_gemma":[0.9935758,0.00298113,0.002061116,0.000481902,0.0003928656,0.0005071691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8762293,0.00172668,0.01000633,0.01027555,0.05605849,0.00007056024,0.0001039045,0.0007423008,0.002649869,0.0001420596,0.001648774,0.04034614],"study_design_scores_gemma":[0.7693917,0.08361153,0.06612289,0.001518651,0.07015625,0.0003203812,0.0001131941,0.001068361,0.00147787,0.0005215025,0.005577187,0.0001204764],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6789225,0.2999586,0.002388292,0.001142588,0.001040748,0.005114361,0.005725748,0.0002226799,0.005484577],"genre_scores_gemma":[0.9636315,0.02733359,0.001464984,0.001089989,0.0007931224,0.002305923,0.002579698,0.00002989786,0.0007713095],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00966309,"threshold_uncertainty_score":0.05110389,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4406295719","doi":"10.25251/skin.9.supp.510","title":"Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years From ADjoin","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research; Queen's University","funders":"Dermira; Eli Lilly and Company","keywords":"Atopic dermatitis; Term (time); Dermatology; Medicine; Physics","authors":[{"name":"Emma Guttman‐Yassky","is_ca":false},{"name":"Alan D. Irvine","is_ca":false},{"name":"Eric L. Simpson","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Stephan Weidinger","is_ca":false},{"name":"Lynda Spelman","is_ca":false},{"name":"Jonathan I. Silverberg","is_ca":false},{"name":"Heidi M. Crane","is_ca":false},{"name":"Hany Elmaraghy","is_ca":false},{"name":"Louise DeLuca-Carter","is_ca":false},{"name":"Maria Lucia Buziqui Piruzeli","is_ca":false},{"name":"Chaoran Hu","is_ca":false},{"name":"Evangeline Pierce","is_ca":false},{"name":"Helena Agell","is_ca":false},{"name":"Diamant Thaçi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.00559892539955492,"gpt":0.2477296975346066,"spread":0.2421307721350517,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002759475,0.0003729259,0.0009979858,0.0001709327,0.0004374622,0.0007463073,0.0003474556,0.0005409337,0.002067499],"category_scores_gemma":[0.001408938,0.0001816324,0.001638599,0.0002556669,0.0002909573,0.0007051518,0.0004806973,0.001213338,0.0005686707],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004676781,"about_ca_system_score_gemma":0.0005146507,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004525623,"about_ca_topic_score_gemma":0.001106643,"domain_scores_codex":[0.9991015,0.0003331605,0.00009272007,0.0001652427,0.0001522948,0.0001551526],"domain_scores_gemma":[0.9983718,0.0003106792,0.0005959579,0.0001881246,0.0001636495,0.0003699141],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.379109,0.01528485,0.3628662,0.001481295,0.003129339,0.0006888358,0.0006304496,0.000910753,0.0449048,0.00009875212,0.00288231,0.1880134],"study_design_scores_gemma":[0.02390257,0.2062729,0.7542085,0.0001440097,0.002015684,0.0009225319,0.000266093,0.0007254234,0.005963034,0.0001173673,0.005402698,0.00005913191],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966839,0.00177264,0.0001054668,0.00006989045,0.00001916145,0.0001855321,0.0003675249,0.00001198155,0.0007839315],"genre_scores_gemma":[0.9977565,0.0003830005,0.0001543276,0.000159847,0.00003512047,0.0001355042,0.000771759,0.000003981559,0.0005999947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002759475,"threshold_uncertainty_score":0.01459366,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3212995571","doi":"10.25251/skin.5.supp.35","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Term (time); Extension (predicate logic); Aryl hydrocarbon receptor; Aryl; Psoriasis; Hydrocarbon; Medicine; Combinatorial chemistry; Pharmacology; Chemistry; Computer science; Dermatology; Organic chemistry; Physics; Biochemistry","authors":[{"name":"Bruce Strober","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"Robert Bissonnette","is_ca":true},{"name":"April W. Armstrong","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Philip Brown","is_ca":false},{"name":"Leon Kircik","is_ca":false},{"name":"Anna M. Tallman","is_ca":false},{"name":"Mark Lebwohl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03423787189915257,"gpt":0.2839932816325126,"spread":0.24975540973336,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001293775,0.001370973,0.003146752,0.0004860223,0.0005543008,0.001026752,0.001012663,0.001731797,0.004718577],"category_scores_gemma":[0.000777029,0.0005399215,0.001915055,0.0004342083,0.001043407,0.001192758,0.0003137277,0.003861709,0.001126219],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006976534,"about_ca_system_score_gemma":0.000972947,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001973649,"about_ca_topic_score_gemma":0.003479365,"domain_scores_codex":[0.9994623,0.0001507171,0.00002512495,0.0001086983,0.00005696338,0.0001961523],"domain_scores_gemma":[0.9994221,0.0001173178,0.00006885125,0.00006559828,0.00004702597,0.0002790953],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8934517,0.03420894,0.0008844681,0.0005986043,0.0008642233,0.0001607989,0.00008106855,0.0005867062,0.01394044,0.0001394637,0.00119839,0.0538852],"study_design_scores_gemma":[0.6245385,0.3616396,0.008518744,0.00007477626,0.0008075213,0.0001715491,0.00006069593,0.0008732403,0.001679398,0.0001862462,0.001409582,0.00004013107],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884583,0.005262356,0.0005563225,0.0005260118,0.000436013,0.001054482,0.0008310034,0.0001401366,0.00273529],"genre_scores_gemma":[0.9875553,0.003948976,0.0008112472,0.0008503646,0.0004387483,0.0009312879,0.001225236,0.00002638165,0.004212357],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004718577,"threshold_uncertainty_score":0.01578522,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3214388010","doi":"10.25251/skin.5.supp.41","title":"Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"","keywords":"Dermis; Plaque psoriasis; Medicine; Roflumilast; Psoriasis; Dermatology; Pathology; Internal medicine","authors":[{"name":"Melinda Gooderham","is_ca":true},{"name":"Javier Alonso‐Llamazares","is_ca":false},{"name":"Jerry Bagel","is_ca":false},{"name":"John Browning","is_ca":false},{"name":"Zoe Draelos","is_ca":false},{"name":"Kimberly Grande","is_ca":false},{"name":"Adelaide A Herbert","is_ca":false},{"name":"Wei Jing Loo","is_ca":true},{"name":"Chih-ho Hong","is_ca":true},{"name":"Mark Lebwohl","is_ca":false},{"name":"Walter K. Nahm","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"David M. Pariser","is_ca":false},{"name":"Jennifer Soung","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"Irina Turchin","is_ca":true},{"name":"Amy Feng","is_ca":false},{"name":"Patrick Burnett","is_ca":false},{"name":"Robert Higham","is_ca":false},{"name":"David R. Berk","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0105701159799711,"gpt":0.3020733013765192,"spread":0.2915031853965481,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00122938,0.0004786845,0.001251828,0.0002085144,0.0002598993,0.0003769583,0.0002585169,0.0004344499,0.002936461],"category_scores_gemma":[0.0007544028,0.0002011909,0.001030848,0.0001772572,0.0002670756,0.0004714071,0.0001548946,0.001059367,0.0002935998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002462695,"about_ca_system_score_gemma":0.0003517644,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006286025,"about_ca_topic_score_gemma":0.002036643,"domain_scores_codex":[0.9996369,0.0002023109,0.00003094339,0.0000325311,0.00003265998,0.00006464926],"domain_scores_gemma":[0.999627,0.0001474364,0.00006839595,0.00003484746,0.00003047817,0.00009183901],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5724951,0.01974224,0.01163113,0.002135165,0.001984829,0.0005905274,0.0002399702,0.000702296,0.09008956,0.0001802318,0.003395235,0.2968137],"study_design_scores_gemma":[0.2639672,0.6191858,0.09289241,0.0002751612,0.002260803,0.001036371,0.0002026054,0.001043515,0.0134623,0.0002348924,0.005385723,0.00005313518],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893995,0.006691975,0.0002337589,0.000422616,0.0001065196,0.0003773504,0.0002153529,0.00005304557,0.002499831],"genre_scores_gemma":[0.9960757,0.002256917,0.0003239428,0.0002546706,0.000102205,0.00009822342,0.0001582629,0.000006770962,0.0007232047],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002936461,"threshold_uncertainty_score":0.009823442,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4404455235","doi":"10.25251/skin.8.supp.473","title":"Bimekizumab Efficacy and Safety Through 2 years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II trials and Open-Label Extension BE HEARD EXT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Geotab (Canada)","funders":"LEO Pharma; InflaRx; Idorsia Pharmaceuticals; European Academy of Dermatology and Venereology; Eisai; Bundesministerium für Bildung und Forschung; Insmed; Incyte; Celgene; Biogen; L'Oreal USA; European Commission; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Hidradenitis suppurativa; Open label; Extension (predicate logic); Phase (matter); Medicine; Dermatology; Internal medicine; Clinical trial; Computer science; Chemistry; Programming language","authors":[{"name":"Christos C. Zouboulis","is_ca":false},{"name":"Amit Garg","is_ca":false},{"name":"Christopher J. Sayed","is_ca":false},{"name":"Gregor B. E. Jemec","is_ca":false},{"name":"Georgios Kokolakis","is_ca":false},{"name":"John R Ingram","is_ca":false},{"name":"Akimichi Morita","is_ca":false},{"name":"Pratiksha Dokhe","is_ca":false},{"name":"Ingrid Pansar","is_ca":false},{"name":"Robert Rolleri","is_ca":false},{"name":"Christina Crater","is_ca":false},{"name":"Asim Datye","is_ca":true},{"name":"Alexa B. Kimball","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07663420508063443,"gpt":0.3691144696220155,"spread":0.2924802645413811,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005473221,0.000936224,0.002282431,0.0003952536,0.0005527225,0.001289682,0.0006972818,0.00147052,0.004624122],"category_scores_gemma":[0.003708798,0.0005115418,0.002923984,0.0005958678,0.0005576512,0.001729009,0.0006826154,0.002749545,0.0007426367],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007399617,"about_ca_system_score_gemma":0.001092431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009891113,"about_ca_topic_score_gemma":0.002448736,"domain_scores_codex":[0.9980692,0.001047934,0.0001580237,0.0002487825,0.0002420701,0.0002339057],"domain_scores_gemma":[0.996821,0.0007329338,0.001149352,0.0002396011,0.0002560508,0.0008010151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8496249,0.01398979,0.01589788,0.002704259,0.005271784,0.0001626688,0.0002929097,0.0008596558,0.005035296,0.0001974416,0.005951341,0.100012],"study_design_scores_gemma":[0.6300596,0.2775742,0.07711872,0.0003953902,0.004758259,0.0003952704,0.0001724072,0.0007229878,0.001606338,0.000334119,0.006774579,0.00008814402],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9467441,0.03793798,0.0006400607,0.001316675,0.0003221298,0.002703722,0.00548594,0.00009108307,0.00475848],"genre_scores_gemma":[0.9766774,0.008728726,0.001212076,0.001860459,0.0008114947,0.002450984,0.005870137,0.0000292708,0.00235938],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005473221,"threshold_uncertainty_score":0.02894551,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392906202","doi":"10.25251/skin.8.supp.375","title":"Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University","funders":"LEO Pharma; European Academy of Dermatology and Venereology","keywords":"Atopic dermatitis; Clinical trial; Medicine; Dermatology; Internal medicine","authors":[{"name":"Kristian Reich","is_ca":false},{"name":"Richard G. Langley","is_ca":true},{"name":"Juan Francisco Silvestre","is_ca":false},{"name":"D. Staumont‐Sallé","is_ca":false},{"name":"Antonio Costanzo","is_ca":false},{"name":"Andrew Pink","is_ca":false},{"name":"Amy S. Paller","is_ca":false},{"name":"Norito Katoh","is_ca":false},{"name":"Andreas Wollenberg","is_ca":false},{"name":"Richard B. Warren","is_ca":false},{"name":"Christian Bjerregård Øland","is_ca":false},{"name":"Ann‐Marie Tindberg","is_ca":false},{"name":"Le Gjerum","is_ca":false},{"name":"Eric L. Simpson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03268452212128633,"gpt":0.3645907165020806,"spread":0.3319061943807943,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02883777,0.0007216037,0.003406659,0.00181339,0.0003346548,0.002595491,0.001164572,0.0007303447,0.00220629],"category_scores_gemma":[0.02463295,0.0005044718,0.00703252,0.003093585,0.0003646243,0.001444632,0.001281431,0.001506663,0.0003335909],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001409438,"about_ca_system_score_gemma":0.002092925,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001197736,"about_ca_topic_score_gemma":0.003134421,"domain_scores_codex":[0.982439,0.007644364,0.002738143,0.002911218,0.003739842,0.0005272991],"domain_scores_gemma":[0.9520419,0.01892236,0.02063325,0.003507381,0.00402092,0.0008742252],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.09127876,0.0005813,0.3487006,0.03575085,0.2031658,0.0002441755,0.000401184,0.007398795,0.006242561,0.001034009,0.02042095,0.2847811],"study_design_scores_gemma":[0.020109,0.01040184,0.6961258,0.005214451,0.2003901,0.001275333,0.0001422539,0.005332809,0.003008922,0.001936996,0.05587015,0.0001924128],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5920278,0.2512555,0.009604075,0.003331494,0.0003108044,0.003592515,0.1312225,0.0006327885,0.008022428],"genre_scores_gemma":[0.8829176,0.0271187,0.007516749,0.001650422,0.0003570464,0.002584939,0.07663868,0.0001566398,0.001059395],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02883777,"threshold_uncertainty_score":0.1525105,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392928302","doi":"10.25251/skin.8.supp.361","title":"Measuring GPPGA, Pain, Symptom, and Quality of Life Index Scores in Untreated Generalized Pustular Psoriasis: Results from the Placebo Group of the Effisayil-2 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Pfizer Pharmaceuticals; Sanofi Genzyme; Regeneron Pharmaceuticals; Meiji Seika Pharma; Eli Lilly and Company; Bristol-Myers Squibb; LEO Pharma; Incyte; Amgen","keywords":"Placebo; Psoriasis; Dermatology Life Quality Index; Medicine; Generalized pustular psoriasis; Quality of life (healthcare); Placebo group; Index (typography); Physical therapy; Dermatology; Alternative medicine; Pathology","authors":[{"name":"Bruce Strober","is_ca":false},{"name":"Arash Mostaghimi","is_ca":false},{"name":"Milan J. Anadkat","is_ca":false},{"name":"Christian Thoma","is_ca":false},{"name":"Ming Tang","is_ca":true},{"name":"Jason R. Guercio","is_ca":false},{"name":"Mark Lebwohl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03282687181193359,"gpt":0.2558931768416337,"spread":0.2230663050297001,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00345738,0.001169785,0.002299914,0.0002594797,0.0003256552,0.001058144,0.0006693827,0.001494636,0.003508145],"category_scores_gemma":[0.00226423,0.000475038,0.002199218,0.000333031,0.0008493958,0.0009523297,0.0004302658,0.00237248,0.0004549454],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004093274,"about_ca_system_score_gemma":0.0005985202,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003473019,"about_ca_topic_score_gemma":0.0005764455,"domain_scores_codex":[0.9985015,0.0009634236,0.00008821901,0.0001870759,0.0001349484,0.0001248523],"domain_scores_gemma":[0.9986489,0.0003783882,0.0004303954,0.0001457551,0.00008386911,0.0003127605],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9575872,0.004469832,0.005743396,0.0007562047,0.002181706,0.00006736824,0.0001004468,0.0002821455,0.003129813,0.00009904709,0.0008510196,0.02473174],"study_design_scores_gemma":[0.867788,0.108464,0.02051046,0.00009061026,0.001305114,0.0001295529,0.00004838426,0.0002807263,0.0004116543,0.0001973431,0.0007526185,0.00002154636],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883486,0.007159473,0.0002447845,0.0004240276,0.0001456914,0.0008893906,0.0009290569,0.00003118405,0.001827783],"genre_scores_gemma":[0.9932105,0.00208951,0.0005077093,0.0004998308,0.0003073325,0.001387823,0.001145733,0.000009150365,0.0008424127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003508145,"threshold_uncertainty_score":0.01828462,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2990965204","doi":"10.25251/skin.3.6.20","title":"Reply: Terra Firma-Forme Dermatosis, Keratotic Form","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Genetic and rare skin diseases.","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SKiN Health","funders":"","keywords":"Dermatology; Medicine; Art","authors":[{"name":"Daniel J. Callaghan","is_ca":true},{"name":"Kenneth A. Arndt","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.004164474139625888,"gpt":0.2242680610396761,"spread":0.2201035869000502,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001345858,0.0009541766,0.001303368,0.0007867609,0.001111952,0.001294249,0.001580078,0.02195569,0.009918524],"category_scores_gemma":[0.01054166,0.0006524794,0.001045063,0.0006459468,0.001933873,0.00242825,0.0008103587,0.01802492,0.006637537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001353592,"about_ca_system_score_gemma":0.001038272,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002799559,"about_ca_topic_score_gemma":0.002366319,"domain_scores_codex":[0.9991378,0.0002713475,0.0001876494,0.0001313369,0.0001454111,0.0001265178],"domain_scores_gemma":[0.9973813,0.001405877,0.0001404661,0.0001260536,0.0006233537,0.0003230396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"case_report","study_design_scores_codex":[0.000186731,0.00003287023,0.001061173,0.0002339182,0.0000283325,0.009930192,0.00009129251,0.0001038431,0.0004253042,0.001002661,0.9798819,0.007021764],"study_design_scores_gemma":[0.0003320027,0.0001844725,0.006088392,0.0006106508,0.000127242,0.03952689,0.0008538232,0.0006757774,0.0007691106,0.006763376,0.9439249,0.0001434155],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.001234577,0.004754953,0.0002579948,0.8981248,0.09280628,0.00005504921,0.0003137793,0.00008204624,0.002370502],"genre_scores_gemma":[0.01737003,0.007094696,0.000639408,0.8402588,0.1189702,0.0001189431,0.0003384812,0.00004818357,0.01516135],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02195569,"threshold_uncertainty_score":0.03318071,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388625689","doi":"10.25251/skin.7.supp.272","title":"Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Dermatology; Atopic dermatitis; Adverse effect; Placebo; Head and neck; Erythema; Surgery; Internal medicine; Pathology; Alternative medicine","authors":[{"name":"Jenny E. Murase","is_ca":false},{"name":"Mónica Munera‐Campos","is_ca":false},{"name":"Hwanhee Hong","is_ca":true},{"name":"Alain Taı̈eb","is_ca":false},{"name":"Wen‐Hung Chung","is_ca":false},{"name":"Amber Reck Atwater","is_ca":false},{"name":"María José Rueda","is_ca":false},{"name":"Jinglin Zhong","is_ca":false},{"name":"Maria Lucia Buziqui Piruzeli","is_ca":false},{"name":"Ignasi Pau‐Charles","is_ca":false},{"name":"Mette Deleuran","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01124778858614377,"gpt":0.2637996245793265,"spread":0.2525518359931828,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005731923,0.0002011113,0.0008706735,0.0001066395,0.0001836958,0.0003198744,0.0001411461,0.0003463834,0.003542288],"category_scores_gemma":[0.001201923,0.0001103309,0.0008781261,0.0001079938,0.0001220599,0.0002897589,0.0001006344,0.0007280657,0.0002616839],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002805112,"about_ca_system_score_gemma":0.0002610763,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005569275,"about_ca_topic_score_gemma":0.001332832,"domain_scores_codex":[0.9996738,0.000132458,0.00004285788,0.00004377208,0.00004979174,0.00005721617],"domain_scores_gemma":[0.9994839,0.0002068552,0.0001290119,0.00003580171,0.00005781634,0.00008652781],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.3821894,0.004923344,0.1010392,0.002325834,0.00407022,0.001530145,0.0002971007,0.0007019478,0.1016888,0.0002456893,0.003451114,0.3975373],"study_design_scores_gemma":[0.0850592,0.2632683,0.6030487,0.0003150425,0.005916357,0.004496336,0.000426512,0.002140354,0.02230293,0.0003346181,0.01261968,0.00007202062],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902021,0.004711668,0.0004030928,0.0002417785,0.000206784,0.0001491763,0.0003614048,0.00006083649,0.003663049],"genre_scores_gemma":[0.998288,0.0004684299,0.0001956434,0.0001461721,0.00004286148,0.00002305451,0.0001342144,0.000003759018,0.000697825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003542288,"threshold_uncertainty_score":0.01185006,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2899771516","doi":"10.25251/skin.2.6.5","title":"Efficacy of a Silicone-Based Gel Containing Pracaxi Oil (Pentaclethra macroloba) for Treating Post-Surgical Scars","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatologic Treatments and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Scars; Silicone; Surgery; Silicone oil; Randomized controlled trial","authors":[{"name":"Mark S. Nestor","is_ca":false},{"name":"Brian Berman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02279922151868099,"gpt":0.3523882437653737,"spread":0.3295890222466927,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007203213,0.000482303,0.0008198719,0.0003446688,0.0002540784,0.000276589,0.0004455396,0.0006039439,0.001808036],"category_scores_gemma":[0.0007278548,0.0002594668,0.0005155536,0.000168062,0.0005135207,0.0003992249,0.0002114791,0.0006821199,0.0001915363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001614936,"about_ca_system_score_gemma":0.0003825288,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004682868,"about_ca_topic_score_gemma":0.0009970621,"domain_scores_codex":[0.999696,0.0001324245,0.00003208282,0.00004366248,0.00005216553,0.00004368847],"domain_scores_gemma":[0.999446,0.0002033114,0.0001427321,0.00003708414,0.0000364142,0.0001344466],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6285669,0.1069153,0.004894256,0.001494194,0.0004394568,0.0002017404,0.0002324251,0.0003076899,0.1709885,0.0001508676,0.0003362373,0.08547246],"study_design_scores_gemma":[0.03811426,0.9422008,0.009877442,0.00002564321,0.0001848695,0.0001052348,0.00005734127,0.0001663894,0.008904088,0.00002978636,0.0003228679,0.00001131057],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984589,0.0007109992,0.0001172134,0.00003230753,0.00003799058,0.0003221125,0.00005303482,0.000007687664,0.0002597851],"genre_scores_gemma":[0.9970796,0.00103,0.0005328379,0.00007136278,0.00009107866,0.0003313888,0.000131577,0.000002837109,0.0007293794],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001808036,"threshold_uncertainty_score":0.006048501,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388627499","doi":"10.25251/skin.7.supp.241","title":"Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SKiN Health","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Psoriasis; Placebo; Clinical endpoint; Apremilast; Clinical trial; Internal medicine; Randomized controlled trial; Tolerability; Adverse effect; Gastroenterology; Dermatology; Psoriatic arthritis","authors":[{"name":"Howard Sofen","is_ca":false},{"name":"Bruce Strober","is_ca":false},{"name":"Shinichi Imafuku","is_ca":false},{"name":"C. Paul","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Lynda Spelman","is_ca":false},{"name":"Seong Jun Seo","is_ca":false},{"name":"Thierry Passeron","is_ca":false},{"name":"Renata M. Kisa","is_ca":false},{"name":"Victoria Berger","is_ca":false},{"name":"Eleni Vritzali","is_ca":false},{"name":"Kim Hoyt","is_ca":false},{"name":"Matthew J. Colombo","is_ca":false},{"name":"Subhashis Banerjee","is_ca":false},{"name":"Matthias Augustin","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"Andrew Alexis","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Mark Lebwohl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03370635970462376,"gpt":0.3210922749445532,"spread":0.2873859152399295,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004397077,0.0007635757,0.001721508,0.000250291,0.0005837412,0.001211489,0.0005601296,0.001112353,0.001509184],"category_scores_gemma":[0.001862702,0.0002816262,0.001810562,0.00035539,0.0004099661,0.001039582,0.0003340814,0.002671143,0.0003689524],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007368333,"about_ca_system_score_gemma":0.0009790433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000603025,"about_ca_topic_score_gemma":0.002115932,"domain_scores_codex":[0.9987385,0.000683032,0.00008916436,0.000165841,0.0001570711,0.0001664917],"domain_scores_gemma":[0.9987153,0.0002901009,0.0003937305,0.0001154571,0.0001299085,0.0003555485],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6706421,0.01492109,0.01360807,0.002309233,0.004432453,0.0003804491,0.000456894,0.002396657,0.02561028,0.0004568557,0.008238106,0.2565478],"study_design_scores_gemma":[0.5507982,0.3368468,0.0831691,0.0003698612,0.003205492,0.001468985,0.0001659207,0.002693504,0.007170412,0.0009837011,0.01301707,0.0001109195],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9727342,0.01943066,0.0006033939,0.0007696229,0.0001484802,0.001344202,0.0008969262,0.0001219579,0.00395061],"genre_scores_gemma":[0.9914819,0.003787139,0.0007161771,0.0006400284,0.0001637798,0.001076077,0.001216157,0.00002047725,0.0008982925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004397077,"threshold_uncertainty_score":0.02325428,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4400930743","doi":"10.25251/skin.8.supp.406","title":"Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Dermira; Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Computer science; Dermatology","authors":[{"name":"April W. Armstrong","is_ca":false},{"name":"Mark Lebwohl","is_ca":false},{"name":"Richard B. Warren","is_ca":false},{"name":"Howard Sofen","is_ca":false},{"name":"Akimchi Morita","is_ca":false},{"name":"Shinichi Imafuku","is_ca":false},{"name":"Mamitaro Ohtsuki","is_ca":false},{"name":"Lynda Spelman","is_ca":false},{"name":"Thierry Passeron","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"Matthew J. Colombo","is_ca":false},{"name":"John Vaile","is_ca":false},{"name":"Eleni Vritzali","is_ca":false},{"name":"Kim Hoyt","is_ca":false},{"name":"Carolin Daamen","is_ca":false},{"name":"Subhashis Banerjee","is_ca":false},{"name":"Bruce Strober","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02818014222467983,"gpt":0.3017047100186793,"spread":0.2735245677939994,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00545247,0.0009278486,0.001443496,0.0003900362,0.0004831209,0.001379657,0.0005756211,0.001116861,0.00147975],"category_scores_gemma":[0.003175817,0.0002958076,0.00250061,0.0004141653,0.0003997899,0.001063679,0.0004587762,0.002224458,0.0004407334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007940336,"about_ca_system_score_gemma":0.0009059453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008510817,"about_ca_topic_score_gemma":0.001815461,"domain_scores_codex":[0.9984266,0.0007013798,0.0001438142,0.00022413,0.0002953467,0.0002089336],"domain_scores_gemma":[0.997252,0.0006340016,0.0009617033,0.0002936528,0.0003523968,0.0005061474],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5631176,0.01682422,0.0571271,0.002806015,0.01326908,0.0004091755,0.0005931089,0.008189062,0.02577118,0.0004400216,0.01368806,0.2977654],"study_design_scores_gemma":[0.3183641,0.3078556,0.323471,0.0005636845,0.01365673,0.001899443,0.0002958142,0.005384705,0.01032321,0.001156692,0.01680399,0.0002249584],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9683244,0.02330727,0.000751548,0.0005350903,0.00009140846,0.0007033639,0.002469041,0.0001087001,0.003709116],"genre_scores_gemma":[0.9863175,0.006004895,0.0005965408,0.0005956026,0.0001532423,0.000537493,0.00464511,0.00002265853,0.001127001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00545247,"threshold_uncertainty_score":0.02883577,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3213872593","doi":"10.25251/skin.5.supp.59","title":"Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"","keywords":"Atopic dermatitis; Interim; Term (time); Interim analysis; Medicine; Dermatology; Pediatrics; Psychology; Internal medicine; Political science; Clinical trial; Physics","authors":[{"name":"Andrew Blauvelt","is_ca":false},{"name":"J.‐P. Lacour","is_ca":false},{"name":"Darryl Toth","is_ca":true},{"name":"Vivian Laquer","is_ca":false},{"name":"Stefan Beissert","is_ca":false},{"name":"Andreas Wollenberg","is_ca":false},{"name":"Pedro Herranz","is_ca":false},{"name":"Andrew Pink","is_ca":false},{"name":"Ketty Peris","is_ca":false},{"name":"Stine Fangel","is_ca":false},{"name":"Hidehisa Saeki","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01493705308753436,"gpt":0.2688596138407451,"spread":0.2539225607532108,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003578746,0.0005100145,0.001621633,0.0003640809,0.0004063156,0.001352886,0.000472598,0.0006373713,0.001671235],"category_scores_gemma":[0.002343715,0.0002207593,0.003578848,0.0004925763,0.0003441807,0.0009042504,0.0004115677,0.001605099,0.0003907223],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006732348,"about_ca_system_score_gemma":0.0008211225,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009164932,"about_ca_topic_score_gemma":0.001767588,"domain_scores_codex":[0.9982663,0.000517496,0.0001967885,0.000245597,0.0003713272,0.0004025753],"domain_scores_gemma":[0.9977772,0.0007403643,0.0006735364,0.0002740996,0.0002624398,0.0002723543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.522154,0.003893855,0.3617046,0.00122282,0.01510901,0.0005055373,0.0002317757,0.002978978,0.009601526,0.0003076699,0.003351678,0.07893846],"study_design_scores_gemma":[0.01734444,0.06795405,0.8880781,0.0001638665,0.01520882,0.0005695503,0.0002058551,0.001299493,0.003338736,0.0002258114,0.005528403,0.00008296416],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904252,0.002901309,0.0004176415,0.0001368406,0.00006792248,0.0001863655,0.003828799,0.00002407063,0.002011854],"genre_scores_gemma":[0.9921339,0.0006592485,0.0002666483,0.0002803149,0.00006896634,0.0001867873,0.00514894,0.0000101919,0.001244991],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003578746,"threshold_uncertainty_score":0.0189265,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388627694","doi":"10.25251/skin.7.supp.271","title":"Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research; Queen's University","funders":"Dermira; Eli Lilly and Company","keywords":"Atopic dermatitis; Dermatology; Medicine","authors":[{"name":"Emma Guttman‐Yassky","is_ca":false},{"name":"Stephan Weidinger","is_ca":false},{"name":"Eric L. Simpson","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Alan D. Irvine","is_ca":false},{"name":"Lynda Spelman","is_ca":false},{"name":"Jonathan I. Silverberg","is_ca":false},{"name":"Hany Elmaraghy","is_ca":false},{"name":"Louise DeLuca-Carter","is_ca":false},{"name":"Maria Lucia Buziqui Piruzeli","is_ca":false},{"name":"Chaoran Hu","is_ca":false},{"name":"Fan Emily Yang","is_ca":false},{"name":"Evangeline Pierce","is_ca":false},{"name":"Laia Bardolet","is_ca":false},{"name":"Diamant Thaçi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006471958431611242,"gpt":0.2525797674709807,"spread":0.2461078090393695,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002049994,0.0002221449,0.0008641927,0.0002308492,0.0003263297,0.0005560658,0.0001947818,0.0003559174,0.001181624],"category_scores_gemma":[0.002059713,0.0001345204,0.001396665,0.0002956914,0.0002072693,0.0004381656,0.0002467609,0.0008589791,0.0002695218],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004227202,"about_ca_system_score_gemma":0.0004779623,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007787328,"about_ca_topic_score_gemma":0.001731385,"domain_scores_codex":[0.9992504,0.0002827001,0.00009284219,0.0001169703,0.0001599461,0.00009723444],"domain_scores_gemma":[0.9985691,0.0005025726,0.0004591512,0.00008807105,0.0001842159,0.0001967564],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0910978,0.00531119,0.5902016,0.001668403,0.002296195,0.00113494,0.0005711039,0.000527704,0.01371351,0.0001704274,0.003561542,0.2897456],"study_design_scores_gemma":[0.00991312,0.06109386,0.9145286,0.0002652304,0.001614408,0.002403594,0.000445607,0.0008686731,0.003333582,0.0001931874,0.00530009,0.00004002364],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920428,0.005131963,0.000215235,0.0002026884,0.00003996538,0.0001843147,0.000379993,0.00002620426,0.001776833],"genre_scores_gemma":[0.998231,0.0007138121,0.0001557322,0.0002422144,0.00003528654,0.00004934142,0.0002936942,0.000002370098,0.0002765044],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002049994,"threshold_uncertainty_score":0.01084155,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4409574408","doi":"10.25251/skin.10.supp.573","title":"Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Bausch Health; LEO Pharma; Galderma; Incyte; Regeneron Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atopic dermatitis; Term (time); Medicine; Pediatrics; Dermatology; Physics","authors":[{"name":"Andrew Blauvelt","is_ca":false},{"name":"Vivian Laquer","is_ca":false},{"name":"Richard G. Langley","is_ca":false},{"name":"Chih-ho Hong","is_ca":false},{"name":"Christian Bjerregård Øland","is_ca":false},{"name":"Le Gjerum","is_ca":false},{"name":"Ann‐Marie Tindberg","is_ca":false},{"name":"Kristian Reich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005786183515752849,"gpt":0.2590034322650996,"spread":0.2532172487493468,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000967325,0.0001809137,0.000534841,0.0001950929,0.000285507,0.0004765488,0.0001498103,0.0003373641,0.001064107],"category_scores_gemma":[0.001113541,0.0001407738,0.0006958453,0.000222346,0.0001624217,0.00029274,0.0001623654,0.0007516694,0.0002596856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004298882,"about_ca_system_score_gemma":0.0005034049,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001018959,"about_ca_topic_score_gemma":0.002346118,"domain_scores_codex":[0.9996401,0.0000949378,0.00004215741,0.00007152407,0.000091371,0.00005980193],"domain_scores_gemma":[0.9992242,0.000133978,0.0003386633,0.00002771418,0.00009094568,0.0001844463],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04896796,0.00530223,0.8209391,0.0007045423,0.001468967,0.0007268033,0.0005647783,0.0005166137,0.008089953,0.00008244601,0.002020003,0.1106166],"study_design_scores_gemma":[0.006043729,0.04733468,0.9378123,0.0001985416,0.001112399,0.00167934,0.0002619055,0.0005316874,0.001281904,0.00004747155,0.00367666,0.0000194187],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965135,0.002435587,0.00005507039,0.00006293808,0.0000141436,0.00005933702,0.000320472,0.000004674849,0.0005343289],"genre_scores_gemma":[0.9982619,0.0006786115,0.000102061,0.0001215011,0.00002387394,0.00006742316,0.0004329367,0.000001391327,0.0003101992],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001064107,"threshold_uncertainty_score":0.005115747,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3004321152","doi":"10.25251/skin.4.supp.60","title":"Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Pharmacokinetics; Medicine; Dermatology; Pharmacology","authors":[{"name":"Lawrence F. Eichenfield","is_ca":false},{"name":"Boni E. Elewski","is_ca":false},{"name":"Ted Rosén","is_ca":false},{"name":"Aditya Gupta","is_ca":true},{"name":"Wendy Cantrell","is_ca":false},{"name":"Radhakrishnan Pillai","is_ca":false},{"name":"Abby Jacobson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01845050729206081,"gpt":0.2905141314512494,"spread":0.2720636241591886,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000675442,0.0002625062,0.0005964951,0.0001775136,0.0001439931,0.000310753,0.0001910979,0.0003763425,0.0006651405],"category_scores_gemma":[0.002184709,0.0001280098,0.0002871343,0.0002133185,0.0002468412,0.0003103589,0.00007515491,0.0007037209,0.0001516427],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000394256,"about_ca_system_score_gemma":0.0005500828,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001221812,"about_ca_topic_score_gemma":0.001249349,"domain_scores_codex":[0.9995833,0.0002023966,0.00003152658,0.00004758947,0.00009416436,0.00004102774],"domain_scores_gemma":[0.9989374,0.0004289966,0.0003588765,0.00006199029,0.0001003329,0.0001122769],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1305482,0.005105674,0.2980536,0.001216424,0.001054291,0.003080314,0.0007974611,0.004212519,0.1037864,0.000779215,0.004352643,0.4470133],"study_design_scores_gemma":[0.005637937,0.1320209,0.809759,0.0002635048,0.001313904,0.006991334,0.0004940649,0.00499656,0.03097839,0.0002610787,0.007219921,0.00006337179],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933174,0.004812398,0.0003495763,0.0001685638,0.00001889413,0.00005963624,0.0003302183,0.00002156434,0.0009216997],"genre_scores_gemma":[0.9979603,0.001323829,0.0001917452,0.00007724504,0.00002557285,0.00002338649,0.0002219985,0.000005569259,0.0001703265],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001221812,"threshold_uncertainty_score":0.003572106,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3105819045","doi":"10.25251/skin.4.supp.113","title":"A Comparative Clinical Demonstration of the Spreadability of Tazarotene Lotion 0.045% versus Trifarotene Cream 0.005%","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Horticultural and Viticultural Research","field":"Agricultural and Biological Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Lotion; Tazarotene; Spreadability; Dermatology; Medicine; Chemistry; Pharmacology; Food science","authors":[{"name":"Zoe Diana Draelos","is_ca":false},{"name":"Emil Tanghetti","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1191770214751348,"gpt":0.3547450848673582,"spread":0.2355680633922234,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001373115,0.0005329372,0.0006159545,0.0005503792,0.000311287,0.0003654278,0.0005323328,0.0008029355,0.006471768],"category_scores_gemma":[0.00263391,0.0002754684,0.0003873548,0.0002644622,0.001045611,0.000826134,0.0002273339,0.0009998807,0.0008366533],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002260213,"about_ca_system_score_gemma":0.0002946724,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006760439,"about_ca_topic_score_gemma":0.0007194925,"domain_scores_codex":[0.9993283,0.0003322103,0.00004044834,0.0001148733,0.0001026636,0.0000815134],"domain_scores_gemma":[0.9970434,0.001693314,0.0002840036,0.000298828,0.0002450896,0.0004353668],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.2981977,0.02239763,0.001923195,0.0005627635,0.0002139131,0.0004629127,0.000301882,0.0004427607,0.6275828,0.0002703538,0.0004924939,0.04715148],"study_design_scores_gemma":[0.01314755,0.8743564,0.01862333,0.0000248273,0.0002562043,0.0006679881,0.0001701337,0.001258346,0.09003265,0.0001084833,0.001324031,0.00002990771],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994276,0.001739791,0.0008618434,0.000118778,0.0001387536,0.0004373796,0.0001694006,0.0000369509,0.002221055],"genre_scores_gemma":[0.9975992,0.0003986311,0.0004073739,0.00005864375,0.00007911717,0.00007752707,0.0001048624,0.000008237793,0.00126648],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006471768,"threshold_uncertainty_score":0.02165025,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4241580772","doi":"10.25251/skin.4.supp.30","title":"Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Medicine; Dermatology; Psoriasis; Baseline (sea); Phase (matter); Randomized controlled trial; Internal medicine; Biology; Physics","authors":[{"name":"Mark Lebwohl","is_ca":false},{"name":"J.Q. Del Rosso","is_ca":false},{"name":"Chih-ho Hong","is_ca":true},{"name":"Anna M Tailman","is_ca":false},{"name":"Leon Kircik","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01703836544243391,"gpt":0.2787548648414456,"spread":0.2617164993990116,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002310486,0.002194904,0.004005601,0.0005245581,0.0004978307,0.001403444,0.001173862,0.001876034,0.008197984],"category_scores_gemma":[0.001955381,0.001059542,0.001925285,0.0006418451,0.001474375,0.001603176,0.0004805646,0.003677997,0.001100508],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007732866,"about_ca_system_score_gemma":0.001272189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001037177,"about_ca_topic_score_gemma":0.001818922,"domain_scores_codex":[0.9990891,0.0004399926,0.00004181562,0.0001591532,0.0001036169,0.0001662808],"domain_scores_gemma":[0.9985043,0.000475627,0.0002710069,0.000157168,0.0001149641,0.000476956],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9733729,0.0105588,0.0005203502,0.0003746012,0.0006480679,0.0000295523,0.00003967582,0.0002120238,0.003128002,0.0000682204,0.0004496947,0.01059818],"study_design_scores_gemma":[0.9161348,0.08006077,0.002343355,0.00002403195,0.0004072631,0.00003162709,0.00001760121,0.0002646409,0.0002698132,0.0001069231,0.0003236869,0.0000155425],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98858,0.004363104,0.000618031,0.0003994662,0.000251483,0.003036853,0.001264594,0.00009847191,0.001387847],"genre_scores_gemma":[0.9845599,0.004291885,0.001668502,0.0008771955,0.0005668576,0.0037434,0.001522344,0.00005390971,0.002715933],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008197984,"threshold_uncertainty_score":0.02742499,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2987175910","doi":"10.25251/skin.3.supp.37","title":"Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Dermatology; Internal medicine; Oncology; Adalimumab; Disease","authors":[{"name":"Kenneth B. Gordon","is_ca":false},{"name":"Richard B. Warren","is_ca":false},{"name":"A.B. Gottlieb","is_ca":false},{"name":"Andrew Blauvelt","is_ca":false},{"name":"Diamant Thaçi","is_ca":false},{"name":"C. Leonardi","is_ca":false},{"name":"Yves Poulin","is_ca":true},{"name":"Marion Boehnlein","is_ca":false},{"name":"Sarah Kavanagh","is_ca":false},{"name":"Catherine Arendt","is_ca":false},{"name":"Kristian Reich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0386763758361398,"gpt":0.3220570760310816,"spread":0.2833807001949418,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008851249,0.001289631,0.004590121,0.0006312795,0.0003680203,0.001751708,0.0007651581,0.001799199,0.002519952],"category_scores_gemma":[0.005877123,0.0006174113,0.008016114,0.0008087711,0.0006041598,0.001311939,0.0005804825,0.002909718,0.0004435691],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007554855,"about_ca_system_score_gemma":0.0009774812,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001172107,"about_ca_topic_score_gemma":0.002229066,"domain_scores_codex":[0.997763,0.001293725,0.0002057376,0.0002869398,0.0002503252,0.0002001106],"domain_scores_gemma":[0.9954339,0.002083753,0.001268731,0.0003980159,0.000302151,0.0005135048],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.8820099,0.0009710522,0.006758161,0.003413899,0.04918279,0.00009738129,0.00008244341,0.002128409,0.003395376,0.0001229773,0.002542755,0.04929483],"study_design_scores_gemma":[0.7612652,0.07411011,0.08328254,0.0008675632,0.07145149,0.0003405999,0.0001132536,0.002320909,0.001727442,0.0007525966,0.00363331,0.0001349775],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.837346,0.1448717,0.002277199,0.001870368,0.000885875,0.002267275,0.006015244,0.0002447035,0.004221621],"genre_scores_gemma":[0.972481,0.01863023,0.001233128,0.0012764,0.0005925047,0.0009094603,0.004014469,0.00004948582,0.0008133192],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008851249,"threshold_uncertainty_score":0.04681039,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4309317883","doi":"10.25251/skin.6.supp.57","title":"Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research; SKiN Health","funders":"","keywords":"Intertriginous; Dermis; Tolerability; Psoriasis; Dermatology; Roflumilast; Medicine; Plaque psoriasis; Discontinuation; Sex organ; Surgery; Internal medicine; Pathology; Adverse effect; Biology; COPD","authors":[{"name":"Laura K. Ferris","is_ca":false},{"name":"April W. Armstrong","is_ca":false},{"name":"J.Q. Del Rosso","is_ca":false},{"name":"Zoe Diana Draelos","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Mark Lebwohl","is_ca":false},{"name":"Kim Papp","is_ca":true},{"name":"Jennifer Soung","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"David Krupa","is_ca":false},{"name":"Robert Higham","is_ca":false},{"name":"Patrick Burnett","is_ca":false},{"name":"David R. Berk","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02331314075009889,"gpt":0.284818307337959,"spread":0.2615051665878601,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002366931,0.0008826333,0.002753776,0.0004399646,0.0002038854,0.0008387799,0.0004794899,0.0007990519,0.002138749],"category_scores_gemma":[0.001657764,0.0004081992,0.002895171,0.0004738236,0.000432682,0.0007791265,0.0002143354,0.001273778,0.0004349386],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004348854,"about_ca_system_score_gemma":0.0004108333,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008890484,"about_ca_topic_score_gemma":0.002500637,"domain_scores_codex":[0.999289,0.0004030842,0.00007511256,0.00009173383,0.00006266751,0.00007823353],"domain_scores_gemma":[0.9991596,0.0003880853,0.000226277,0.00005648422,0.00004959248,0.0001199585],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.7773747,0.002961541,0.009688733,0.006242018,0.02080531,0.0002410866,0.0001707652,0.002064501,0.0200637,0.0001479788,0.003295273,0.1569444],"study_design_scores_gemma":[0.7199031,0.1624314,0.0845155,0.0006265629,0.02201053,0.0007132196,0.0001884845,0.001821503,0.003186245,0.000409074,0.00407344,0.0001208934],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.919799,0.07295195,0.0006698513,0.0005363742,0.0003019403,0.0005472541,0.001339557,0.0001332342,0.00372083],"genre_scores_gemma":[0.9878593,0.00939949,0.0003728001,0.0004618737,0.0002273544,0.0002305602,0.0007609551,0.00001606499,0.0006714386],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002753776,"threshold_uncertainty_score":0.01251769,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3104939465","doi":"10.25251/skin.4.supp.102","title":"Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"","keywords":"Concomitant; Atopic dermatitis; Medicine; Dermatology; Randomized controlled trial; Internal medicine","authors":[{"name":"Stephan Weidinger","is_ca":false},{"name":"Jonathan I. Silverberg","is_ca":false},{"name":"Darryl Toth","is_ca":true},{"name":"Thomas Bieber","is_ca":false},{"name":"Andrew Alexis","is_ca":false},{"name":"Boni E. Elewski","is_ca":false},{"name":"Andrew Pink","is_ca":false},{"name":"DirkJan Hignen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01553185210748632,"gpt":0.2618408314692068,"spread":0.2463089793617205,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001184426,0.0008067237,0.00125788,0.0001708508,0.0002902895,0.0008668731,0.0004542802,0.0008437146,0.002452089],"category_scores_gemma":[0.0009810812,0.0002834087,0.001760052,0.0002362651,0.0004742059,0.0007533158,0.0001820049,0.002334865,0.0005042951],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005643465,"about_ca_system_score_gemma":0.0006180606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008189366,"about_ca_topic_score_gemma":0.002872174,"domain_scores_codex":[0.9996837,0.0001356181,0.00002654603,0.00005845573,0.00003822136,0.00005739375],"domain_scores_gemma":[0.9993972,0.0001623958,0.0001677328,0.00004228647,0.0000424423,0.0001879565],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.883515,0.005569623,0.006571682,0.002119613,0.004510548,0.0001726738,0.0001668167,0.001266343,0.01126158,0.00015923,0.002919751,0.08176712],"study_design_scores_gemma":[0.7815207,0.1534053,0.05347713,0.0002530229,0.004038491,0.0006480569,0.0001351075,0.001459894,0.001556562,0.0003295607,0.003114647,0.00006148106],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860307,0.01081964,0.0001682123,0.0004632066,0.0001421179,0.0003116985,0.0006554503,0.00004513102,0.001363866],"genre_scores_gemma":[0.9942017,0.003044449,0.0003410417,0.0005219453,0.000148111,0.0002399999,0.0006443762,0.000009038053,0.0008492891],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002452089,"threshold_uncertainty_score":0.00820303,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2986312172","doi":"10.25251/skin.3.supp.39","title":"Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Certolizumab pegol; Placebo; Medicine; Psoriasis; Plaque psoriasis; Randomized controlled trial; Multicenter study; Internal medicine; Dermatology; Adalimumab; Pathology; Alternative medicine","authors":[{"name":"Andrew Blauvelt","is_ca":false},{"name":"Bruce Strober","is_ca":true},{"name":"Richard G. Langley","is_ca":true},{"name":"Sarah Kavanagh","is_ca":false},{"name":"Catherine Arendt","is_ca":false},{"name":"Marion Boehnlein","is_ca":false},{"name":"Mark Lebwohl","is_ca":false},{"name":"Kristian Reich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02894658660659985,"gpt":0.2972223779139177,"spread":0.2682757913073179,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008733111,0.001356329,0.004256478,0.000587333,0.0004240258,0.00132435,0.0008109319,0.002149747,0.003357616],"category_scores_gemma":[0.00764849,0.0007985915,0.005025735,0.0006975676,0.0008926615,0.001414271,0.0004318883,0.002615171,0.0006266401],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005374987,"about_ca_system_score_gemma":0.0007041341,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005159294,"about_ca_topic_score_gemma":0.0006079936,"domain_scores_codex":[0.9975845,0.001349194,0.0002721252,0.0003646803,0.0002872598,0.0001422569],"domain_scores_gemma":[0.9932806,0.002932679,0.002118346,0.0006066155,0.0005175245,0.000544193],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9094241,0.001344953,0.004545648,0.004323327,0.02258061,0.00007487448,0.0000904781,0.001233812,0.007294633,0.00007842619,0.001311765,0.04769734],"study_design_scores_gemma":[0.7878245,0.121293,0.05084507,0.0006421666,0.03053155,0.0003916112,0.00009374955,0.001314698,0.003965198,0.0005250301,0.002474922,0.00009861309],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8637459,0.1202305,0.003688512,0.001138844,0.0007246833,0.002568325,0.004378397,0.0003396381,0.003185173],"genre_scores_gemma":[0.9795521,0.01422581,0.001365744,0.0007159655,0.0004826367,0.0007927772,0.002113633,0.00004704538,0.0007043938],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008733111,"threshold_uncertainty_score":0.04618567,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3085571220","doi":"10.25251/skin.4.supp.42","title":"Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"XBiotech; Kyowa Kirin Pharmaceutical Development; National Institutes of Health; Incyte; Dermira; Valeant Pharmaceuticals International; Celgene; Allergan; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Post-hoc analysis; Psoriasis; Post hoc; Medicine; Internal medicine; Dermatology","authors":[{"name":"Mark Lebwohl","is_ca":false},{"name":"Nehal N. Mehta","is_ca":false},{"name":"Alice B. Gottlieb","is_ca":false},{"name":"Alan M. Mendelsohn","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0407345546950072,"gpt":0.3128386053145739,"spread":0.2721040506195667,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008578146,0.001276491,0.004055087,0.0005173659,0.0006170292,0.001725589,0.0008363604,0.001039334,0.003249745],"category_scores_gemma":[0.004126742,0.0005172081,0.006481163,0.0006603351,0.0006747771,0.001573073,0.000691388,0.002488282,0.0004123551],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006580753,"about_ca_system_score_gemma":0.0009403331,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001243167,"about_ca_topic_score_gemma":0.002925759,"domain_scores_codex":[0.9952335,0.002874292,0.0002904873,0.0005235118,0.000362385,0.0007159764],"domain_scores_gemma":[0.9940304,0.003233459,0.001059749,0.0008014582,0.0003864196,0.0004884359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9229664,0.001734248,0.03000166,0.00050506,0.02118137,0.00009595737,0.0001054968,0.001675979,0.007626997,0.00009734419,0.001139833,0.01286966],"study_design_scores_gemma":[0.1534932,0.2287125,0.5370563,0.0001770477,0.05733253,0.0003205177,0.0003788569,0.0070145,0.009428178,0.000774973,0.005095833,0.000215579],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914349,0.004309572,0.0007108012,0.0001609019,0.0001323468,0.0003982282,0.001636345,0.00004710152,0.001169852],"genre_scores_gemma":[0.9966686,0.0005126079,0.000297088,0.0001396935,0.00008952902,0.0003229501,0.001017193,0.00002646021,0.0009258264],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008578146,"threshold_uncertainty_score":0.04536617,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2765131124","doi":"10.25251/skin.2.supp.54","title":"Omalizumab Retreatment of Patients with Chronic Idiopathic Urticaria/Spontaneous Urticaria (CIU/CS) Following Return of Symptoms: Primary Results of the Optima Study","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada; European Academy of Allergy and Clinical Immunology","keywords":"Medicine; Chronic urticaria; Omalizumab; Dermatology; Primary care; Immunology; Immunoglobulin E; Antibody; Family medicine","authors":[{"name":"Gordon Sussman","is_ca":false},{"name":"Jacques Hébert","is_ca":false},{"name":"Wayne Gulliver","is_ca":false},{"name":"Charles Lynde","is_ca":false},{"name":"William H. Yang","is_ca":false},{"name":"Olivier Chambenoit","is_ca":false},{"name":"António Vieira","is_ca":false},{"name":"Frederica DeTakaosy","is_ca":false},{"name":"Lenka Řihakova","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005904810974161413,"gpt":0.2346256141413623,"spread":0.2287208031672009,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001399207,0.0003132567,0.001367615,0.0002692711,0.0002567395,0.0005743338,0.0003093825,0.0005156206,0.0008385289],"category_scores_gemma":[0.001683435,0.0002041552,0.0009640428,0.0001978134,0.0002515017,0.0004457803,0.0001823264,0.0007521288,0.0002504426],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002983248,"about_ca_system_score_gemma":0.0003017172,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006871258,"about_ca_topic_score_gemma":0.001200008,"domain_scores_codex":[0.999598,0.0001752847,0.00003819061,0.00005160885,0.0000715579,0.0000653539],"domain_scores_gemma":[0.9992092,0.0002574593,0.000251615,0.00006014642,0.00004134934,0.00018029],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3172922,0.0144962,0.3415571,0.00192836,0.005205141,0.001208981,0.0006270533,0.0007066001,0.01362302,0.0002020938,0.004290255,0.2988631],"study_design_scores_gemma":[0.03634772,0.07424082,0.8795635,0.0001764161,0.002871616,0.001835333,0.000279337,0.001050129,0.001318805,0.0001694678,0.002100037,0.00004677027],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962871,0.002710241,0.0000361787,0.0001042425,0.00003067289,0.00005421028,0.0001284867,0.000008955916,0.0006400108],"genre_scores_gemma":[0.9987087,0.000626241,0.0001031891,0.0001012153,0.00005917615,0.00002732709,0.00017312,0.000002075147,0.0001989623],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001399207,"threshold_uncertainty_score":0.007399797,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4324057774","doi":"10.25251/skin.7.supp.111","title":"Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Cohort; Roflumilast; Internal medicine; Psoriasis; Randomized controlled trial; Open label; Surgery; Dermatology; COPD","authors":[{"name":"Mark Lebwohl","is_ca":false},{"name":"Linda Stein Gold","is_ca":false},{"name":"Melinda Gooderham","is_ca":true},{"name":"Kim Papp","is_ca":true},{"name":"Laura K. Ferris","is_ca":false},{"name":"David Adam","is_ca":true},{"name":"Hwanhee Hong","is_ca":true},{"name":"Leon Kircik","is_ca":false},{"name":"Matthew Zirwas","is_ca":false},{"name":"Patrick Burnett","is_ca":false},{"name":"Robert Higham","is_ca":false},{"name":"David Krupa","is_ca":false},{"name":"David R. Berk","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05145775588564373,"gpt":0.3755849522784312,"spread":0.3241271963927875,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003995292,0.001131894,0.001692116,0.0003098758,0.000499052,0.0009113137,0.0005397242,0.001144535,0.004006931],"category_scores_gemma":[0.002078291,0.0004099708,0.001258238,0.0002979011,0.0004593247,0.0008852278,0.0003463811,0.002735053,0.0009768682],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005563306,"about_ca_system_score_gemma":0.001015034,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004098264,"about_ca_topic_score_gemma":0.0009945248,"domain_scores_codex":[0.9989713,0.0004089111,0.00009638644,0.0002128948,0.0001685768,0.0001419545],"domain_scores_gemma":[0.9983023,0.0003705095,0.0004833211,0.000168561,0.0001659508,0.0005093859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8173406,0.04496484,0.0172883,0.0008312587,0.001522497,0.0001966285,0.0003154022,0.0005907273,0.03329216,0.00009781426,0.003527064,0.08003277],"study_design_scores_gemma":[0.5055598,0.4385423,0.04794697,0.00007603122,0.000922055,0.0003480861,0.0000507492,0.0005210185,0.003473472,0.0001140969,0.002412661,0.00003278289],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922343,0.002717952,0.000367228,0.0002655718,0.0000726364,0.001485218,0.001564817,0.00005989164,0.001232414],"genre_scores_gemma":[0.9919083,0.001273174,0.0008321758,0.0005174852,0.000244162,0.001558244,0.002659232,0.00001991586,0.000987398],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004006931,"threshold_uncertainty_score":0.02112943,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}